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Increasing demand of medical implants has lead researchers to develop 
biomaterial surfaces that offer improved performance and lower thrombogenecity. There 
have been attempts to model biomaterial surfaces after the native endothelium as it 
represents an optimal non-thrombotic surface. Typically, when biomaterials are contacted 
with blood, they often invoke the activation of clotting cascades. Thus, to overcome 
surface mediated thrombotic events, proteins and molecules with anticoagulant attributes 
of the endothelium have been immobilized onto biomaterial surfaces. Protein C (PC) 
plays a main role in blood coagulation and acts as an anticoagulant when it is converted 
into activated protein C (APC). Activation of PC can be initiated only by thrombin (TR)-
thrombomodulin (TM) complex with a relatively slower reaction, and is enhanced 20-
fold when EPCR, the co-factor to PC, is also present. The objective of this thesis is to 
generate a chimeric protein that includes the functional domains of both EPCR and TM in 
an attempt to generate APC in-situ. The synthetic genes encoding the functional domains 
of EPCR (1-193) and TM (224-462) with either a myc or flag linker along with a 
histidine tag were first assembled by PCA/PCR method, sequenced and the synthetic 
genes encoding the correct sequences for chimera I, chimera II, and TM2-His were 
successfully expressed in yeast Pichia host X-33 strain. Expressed protein was analyzed 
by Western blotting analysis, purified using Ni-chelate chromatography, and the ability 
of EPCR-TM chimera to catalyze PC activation was tested in solution phase. Overall, the 
expression level of chimera I, chimera II, and TM2-His was low, and mature proteins 
were partially secreted into the medium, and His-tag purification yielded partially pure 
products. Chimera containing EPCR and TM was noted to generate 1.8-fold higher APC 
compared to standard TM at comparable concentrations. 
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Introduction 
Biomedical implants and devices play a significant role in maintaining and 
improving human health.  Further, the demand of medical implant devices, including 
heart valves, vascular grafts, stents, and catheters, has been steadily increasing over past 
century to save millions of patients[1-3], and a variety of synthetic polymeric materials 
has been developed to be more biocompatible such as Dacron®, polytetrafluoroethylene 
(PTFE), polyurethane (PU) and biodegradable materials [4].  Polymers such as Dacron® 
and PTFE have been widely used for large vessels (7-9 mm) with a 45% of patency 
compared to 60 to 80% patency of autologous vein grafts, however, patency of Dacron® 
and PTFE is far lower in smaller diameter grafts (<6 mm), 20-25%  patency with 1 mm 
diameter microvessels[5].  The reason is that these biomaterials activate thrombus 
formation on its lumen while the differential compliance at the anastomotic site 
contributes to the formation of intimal hyperplasia (IH)[6].  Newer material, polyurethane 
(PU), a radially compliant polymer, has been developed to reduce the occurrence of 
intimal hyperplasia at the anastomotic site [7].  Since the porosity of biomaterials is a key 
factor for the failure in small diameter grafts due to hyperplasia, it is imperative to 
produce PU with porosity of 0.6 to 5.0 μm [8].  The patency rate in the pore sizes larger 
than 5.0 μm was 75% and that of pore sizes smaller than 2.0 μm was 50%.  This study 
indicated that microvenous polyurethane-based prostheses with a luminal pore size larger 
than 5.0 μm yielded a better patency rates than prostheses with a luminal pore size 
smaller than 5.0 μm.  Other interesting materials are biodegradable polymers such as 
polylactic acid (PLA), plyglycolic acid (PGA), polyhydroxyalkanotae (PHA), and 
plydioxanone (PDS)[6].  Even though these polymers possess the mechanical strength 
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comparable to that of native vessel, researchers have been focusing on the control of 
degradation rate to slow down absorption and allow sufficient time for arterial 
regeneration for a long term patency[9].  An alternative strategy to improve synthetic and 
degradable vascular grafts is the manipulation of proteins that compose native 
extracellular matrix (ECM).  Collagen gels and fibers from type I collagen, a major ECM 
component in the blood vessel, are widely used to improve the mechanical strength of 
grafts  by preventing critical rupture of the vascular wall[10].  To overcome the limitation 
of stiff collagen-based biopolymers, researchers have been exploring the elastic fibrin 
gels [11], which can be produced from the patients’ own blood to prevent an 
inflammatory reaction due to the implantation[12].  These grafts remained in the vein of 
lambs for 15weeks and contained both collagen and elastin without any toxic 
degradation.  The mechanical properties were comparable to that of native coronary 
arteries[13].  
When these biomaterials are exposed to blood, they can cause numerous and 
complex responses, including coagulation, complement activation, platelet adhesion and 
activation leading to thrombosis, leukocyte adhesion, and red cell interactions that can 
produce hemolytic damage[14].  To overcome these complications caused by 
biomaterials, researchers have been focusing on resolving the early complication such as 
coagulation and thrombosis since they can be prevented by controlling the initial protein 
adsorption to eliminate undesirable response for example fibrinogen interaction with 
platelets.  One of the two major approaches for protein adsorption control is the surface 
grafting with polyethylene oxide (PEO), which can keep the non-specific proteins away 
from a surface by steric exclusion or by binding water or by phospholipid/phospholipid-
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like layers[15].  The other approach is the promotion of the selective and exclusive 
binding of proteins, which results in attaining a desired specific biological activity [14].  
For example, heparin is immobilized on the biomaterial surface to attract antithrombin III 
that binds to thrombin, so that the surface can provide an anticoagulant effect [16].  
Another example is using lysine to convert plaminogen or tissue plasminogen activator 
(t-PA) into plasmin, a clot dissolving enzyme in the body.  Therefore, maintenance of 
hemocompatibility on the biomaterial surfaces has been one of the main issues in a long 
term use[3, 4], and researchers have been taking direction in the development of 
completely inert biomaterial surface against blood with a limited success [17, 18].  To 
better understand the body response against blood contacting biomaterials, it is important 
to review how the extrinsic and intrinsic pathways of blood coagulation contribute to 
generation of thrombosis.   
In the traditional view of blood coagulation, the initiation phase is triggered by the 
extrinsic pathway, while amplification requires the intrinsic pathway[19].  At site of 
vessel injury, disruption of endothelium exposes platelets to collagen in the vessel wall 
and plasma factor VII/VIIa (FVII/FVIIa) to the integral membrane protein tissue factor 
(TF).  When TF complexes with plasma factor VIIa in the extrinsic pathway, initiation of 
fibrin formation occurs.  Alternatively, coagulation can be initiated through the intrinsic 
pathway when factor XII is activated on a charged surface by contact activation [20].  
Activation of factor XII is followed by activation of factor XI and factor IX.  The 
extrinsic and intrinsic pathway converges at the activation of factor X.  Factor Xa 
activates prothrombin to thrombin in the presence of the cofactor factor Va, and thrombin 
converts fibrinogen to fibrin, forming blood clot. Thrombin is a key regulator for 
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coagulation pathway and triggers anticoagulant pathway by forming a complex with 
thrombomodulin. Thrombin-thrombomodulin complex converts protein C to activated 
Protein C that can form a complex with protein S to inactivate activated factor Va and 
activated factor VIIa. Figure 1 shows the schematic representation of blood coagulation 
and anti-coagulation pathway and this study is focused on the anti-coagulation pathway. 
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Figure 1.   Schematic representation of blood coagulation and anti-coagulation 
pathway 
 
To delay or reduce early clot formation on the biomaterial surface, researchers 
have been attempted to produce biomaterial surfaces to provide anticoagulant activity at 
the level of native endothelium [21-23]. A healthy endothelium demonstrates an 
outstanding thromboresistancy due to soluble molecules (prostacyclin, nitric oxide, and 
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antithrombin III) and membrane bound molecules (heparin sulphate (HS), 
thrombomodulin)[3].  When a biomaterial, immobilized with prostacyclin (PGI2), was 
contacted with blood, PGI2 started to fuse into blood stream to prevent the aggregation 
and release of platelets [24].  It is very powerful material, but PGI2 is an expensive and 
unstable product because its life time is less than 1min after hydrolysis under biological 
conditions.  Thus, this type of biomaterial is not practical, yet.  Another molecule that 
inhibits platelet activation is nitric oxide (NO).  NO releasing peptide was added into the 
main chain of polyurethane to improve thromboresistance [25].  Release of NO lasted for 
two months to reduce platelet adhesion and smooth muscle cell growth, while NO release 
stimulated endothelial cell proliferation.  Inhibition of platelet adhesion is important in 
the extrinsic coagulant pathway, whereas control of thrombin is essential in the common 
coagulation pathway.  In this sense, heparin was coated onto polymeric materials to 
obtain an antithrombogenic function, which enhanced the binding of  antithrombin III 
(AT III) and thrombin, thus preventing blood coagulation [26].  The results showed that 
the heparin release from Biomer/poly (NiPAAm)-coated surfaces significantly reduced 
thrombus formation on test surfaces in contact with venous blood by neutralization of 
thrombin and factor Xa.  As mentioned above, thrombin is a key enzyme in coagulation 
pathway  and also plays an important role in anticoagulant pathway[27].  For this reason, 
recombinant human thrombomodulin (TM), forming a 1:1 molar complex with thrombin, 
has been immobilized on the expanded polytetrafluoroethyelen (ePTFE) by either a direct 
coating or two-step binding process [28].  In this study, the two-step binding method rTM 
activated protein C by 6000-fold compared to the buffer control and 50-85% more than 
direct coating method because modified ePTFE surface immobilized rTM better to 
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stabilize APC.  This result supports that TM has an excellent anticoagulant function on 
endothelium to generate activated protein C (APC) in the presence of thrombin[29].  To 
emphasize the roles of TM in blood coagulation, it is necessary to review previous 
studies on TM.  These studies have explored the catalytic function of TM onto 
membrane-mimetic polymer film that mimics the native endothelium by immobilizing  
TM alone [30], a combination of TM and heparin [22] and TM, heparin and nitric oxide 
(NO), which is capable of generating APC to inactivate factor Va and factor VIIIa.  
Tseng et al designed a membrane-mimetic film containing TM by a photopolymerization 
process to generate actively antithrombogenic surfaces.  The result demonstrated that 
increasing shear and TM surface concentration enhances the rate of protein C activation 
per unit surface area.  Tseng et al also immobilized TM and/or heparin onto the same 
surface above to compare the thrombin production, which resulted in complete 
elimination of steady-state thrombin responses by surface bound TM and heparin, and the 
lowest thrombin generation was observed by TM-mediated activated PC than by heparin-
mediated activation of ATIII.  Wu et al immobilized TM alone on the outer polymer 
coating over the inner NO release film, and TM and heparin were immobilized on the 
same NO releasing film to examine the biological activities of TM and heparin by APC 
generation and anti-factor Xa assay.  In this work, a decreased amount (19.8+/- 2.7%) of 
platelet adhesion was observed by employing NO releasing polymeric coating compared 
with polymer without NO release, while TM, anticoagulant agent, and heparin, enhancing 
binding affinity for ATIII and thrombin, regulate the down-stream of coagulation cascade 
.   It is crucial to review the mechanism of anticoagulant pathway, which is initiated by 
thrombin (TR)-thrombomodulin(TM) complex to activate protein C (PC).    
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PC is a 62kDa plasma glycoprotein that a disulfide bond is holding a 42kDa 
heavy chain and a 21kDa light chain together [31].  The composition of PC is a gamma-
carboxyglutamic acid residue (Gla)-rich domain, 2 epidermal growth factor (EGF)-like 
domains, a short activation peptide, and the serine protease domain (SP) [32].  The Gla 
domain of PC binds to calcium,  negatively charged phospholipid membranes and 
EPCR[33].  PC circulates in blood as a zymogen form of serine protease and PC 
functions as an anticoagulant when it is converted to activated protein C (APC) by 
thrombin bound thrombomodulin complex on the endothelial cell surface [34-36].   To 
initiate the PC anticoagulant pathway, TR needs to bind TM with the high affinity 
resulting in >1000-fold increase of the rate of PC activation [37].   TM is a single chain 
endothelial cell surface glycoprotein with a molecular weight of 74kDa[38]  functioning 
as a potent anti-coagulant by converting TR from a procoagulant protease to an 
anticoagulant.   The mRNA of TM is about 4kb in length, while the cDNA is 1,728bp 
long and encodes a protein of 575 amino acids[39]. TM consists of several domains: an 
N-terminal domain followed by 6 repeated epidermal growth factor (EGF)-like domain, a 
Ser/Thr-rich region containing chondroitin sulfate side chain, a transmembrane section, 
and a short cytoplasmic tail[32].  The region the fourth, fifth and sixth EGF-like domains 
of TM has the ability to bind thrombin and activate protein C[40].  The fourth EGF-like 
domain interacts with serine protease domain of PC[32, 40] while TR binds to the fifth 
and sixth EGF-like domains of TM [41].  In addition, the chondroitin sulfate of TM has 
shown unique effects on its interaction of thrombin, including accelerated reaction of 
thrombin with antithrombin III and enhanced blocking of procoagulant functions[40].  
Soluble TM with chondroitin sulfate demonstrated 5-10-fold increase in thrombin affinity 
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compare with TM lacking the chondroitin sulfate[40], however, the rate of PC activation 
by TR-TM complex is relatively low affinity reaction (Kd = 0.7-1.0uM)[42].  On the 
other hand, generation of APC is significantly increased with a high affinity reaction 
(Kd= 30nM)[37] when TR-TM complex is co-existed with endothelial Protein C Receptor 
(EPCR), a cell-specific type I transmembrane glycoprotein that has an ability to binds 
both PC and APC on the cell surface and was identified by Esmon and Fukudome[43, 
44].  A 43kDa soluble EPCR is identified in human plasma, circulating at a concentration 
of 2.5nM[45].  The genomic DNA of EPCR is about 6kb [46] and the length of mRNA is 
about 1.4kb, while the cDNA has 717 nucleotides encoding a protein of 238 amino acids 
[43].  PC binding to EPCR is mediated by the vitamin K-dependent Gla domain that is 
able to bind to negatively charged phospholipid surface[47].  Binding of PC to EPCR is 
also Ca2+ -dependent, which helps Gla residues to position for assisting hydrogen 
bonding interaction with EPCR[48].  When Gla domain of PC binds to EPCR, a 
hydrophobic pockets of EPCR opens up to accommodate Phe4 of PC Gla domain[48].  
The crystal structure of EPCR showed that the C-terminal of EPCR would be inserted 
into the membrane, whereas APC would bind at the opposite end of EPCR and point 
away from the membrane surface[48].  The Gla-domain of PC/APC interacts with 
EPCR[33], and the Gla-domain of PC also interacts with TM and/or TR[49] and with the 
phospholipid membrane.  To integrate TR, TM, PC, and EPCR on a biomaterial surface 
providing an efficient anticoagulant activity, a multiple protein immobilization technique 
is required.  
To immobilize multiple proteins and biomolecules, a number of methods have 
been developed and used for biosensors, biodiagnostics, genomincs, proteomics, 
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cytology, material science, and general chemistry [50].  However, challenges remain in 
the development of methods such as providing selectivity in biomolecule binding and 
positioning, preserving biological activity, and avoiding non-specific biomolecule 
binding on the micro-scale to nano-scale surfaces [51].   Among these techniques, dip-
pen nanolithography provides a flexible nanolithographic method capable of positioning 
molecules on a substrate with 10 nm resolution [51, 52].  To attach proteins through the 
reactive group on the substrate, covalent coupling is employed by chemical reactions; 
however these chemical reactions can involve residues to affect the activity of the 
proteins [53].  Thus, more site-specific technique has been applied by using monoclonal 
antibodies [54].  This approach recognizes the protein of interest without affecting the 
function of protein, but the size of antibodies is too large to be suitable for high-
resolution structured surface fabrication.   Most of all these techniques is required to 
shield the surface of the substrate with protein compatible layers to avoid the 
denaturation of protein caused by the interaction with solid substrate because these 
techniques are limited on silica chips, gold and galss-type surfaces, which cannot be used 
in human body as a biomaterial [55].  From the review above, a site-specific 
immobilization of multiple proteins is important to make all the proteins perform their 
functions on the biomaterial surfaces providing an efficient anticoagulant activity.   The 
active site of TR (5.5nm diameter)[40] bound to fourth and sixth EGF-like domain of TM 
is positioned about 6.5nm above the membrane[56], and the active site of APC (5.7nm 
diameter)[57] bound to EPCR  is located about 9.4nm above the phospholipid 
membrane[58].  To catalyze the conversion of PC to APC by TR, the active site of TR 
needs to be positioned between 0.7nm and 1.0nm with respect to the activation peptide 
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region of PC [59, 60]  In these studies, the natural anticoagulant components, EPCR and 
TM, of the endothelial surface were sequentially and orderly immobilized via bi-dentate 
moiety grafted onto a biomedical–grade  polyurethane surface within a molecularly 
relevant physical distance, less than 10nm, to support the enzymatic reaction and the rate 
of PC activation from sequential immobilization was compared to that of random 
immobilization.  To achieve properly orientated EPCR on the PU surface, RCR-2 (mAb 
against EPCR) was used to bind carboxyl terminal of EPCR to keep the PC-binding site, 
NH2 terminal,  away from the material surface [61].  The attachment of TM and EPCR 
was controlled by the functional group at the end of the bi-dentate bridge with fast 
coupling reaction to attach TM via carboxyl moiety followed by the slower reaction, the 
nucleophilic reaction, to attach EPCR via oxirane moiety.  The result showed that the 
amount of APC generation from co-immobilization of TM and EPCR via bi-dentate 
bridge is statistically higher level with P < 0.05 compared to that of random 
immobilization.  A smart design of these studies provided an equivalent distribution of 
TM and EPCR due to the defined immobilization sites and eliminated a chemical grafting 
of second protein to the first protein by conducting a fast coupling reaction followed by a 
slower reaction, the nucleophilic addition through an oxirane surface group that is not 
found on proteins or biomolecules to avoid creation of the protein-protein grafting.  
However, this method has several limitations in immobilization of proteins: (1) It is hard 
to guarantee that attachment of bidentate moiety bridge on the backbone of PU surface is 
one hundred percent successful, which means one can have either carboxyl moiety or 
oxirane moiety instead of having both moiety. If the distance between two single moieties 
with corresponding proteins is close enough, they would activate the protein C exactly 
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like a bidentate bridge with both TM and EPCR does.  (2)  It is hard to check the 
distribution of bidentate moiety bridges on the PU surface, which means that bidentate 
bridges can be populated on a small area of PU instead of spreading out evenly on the PU 
surface.  If one can modify the PU surface with bidentate bridge evenly, the rate of APC 
generation would significantly be improved.  (3) It is hard to control the distance between 
two bidentate moiety bridges, which means that some of bidentate bridge might be too 
close to each other or vice versa.  If the distance between two bidentate bridges is too 
close to each other, molecules might have a problem with serve as they should because of 
their limited spatial arrangement.  If the distance between two bidentate bridges is too far 
from each other, it would not be enough to create a significant change in amount of APC 
generation.  To ensure immobilization of two major proteins on the biocompatible 
surfaces within an enzymatically relevant distance without any chemical reactions, this 
research proposes a production of chimera protein containing both TM and EPCR.  This 
chimeric protein created with EPCR and TM using a linker protein in between and six 
additional His tag were attached at the end of TM sequence. It is important to review how 
to design chimeric protein and the choice of the expression system.  
 A recombinant DNA technology with recently improved methods of DNA 
chemical synthesis allows design and relatively rapid synthesis of modest-sized genes, 
and  chimeric/fusion protein techniques are widely used tools in biochemical research to 
increase the expression of soluble proteins and to facilitate protein purification[62]. To 
create chimeric/fusion proteins, parts of two or more different genes encoded for separate 
proteins are connected by a peptide linker[62].  An adequate cushion distance is often 
required when designing the linkers[63]. The length of the linkers varied from 2 to 18 
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residues and the average length was 5.15 residues[64].  Arai et al. showed that chimeric 
proteins with helical linkers were more elongated than those with flexible linkers, but 
flexibility of liker did not reflect the flexibility in the inter-domain distance[65].  The 
difference between flexible and helical liker represented the spatial separation of the two 
domains in the chimeric proteins, and these linkers play an important role in chimeric 
protein to control the distance, orientation, and relative motion of two functional domains 
proteins[63, 65].  Number of studies has been reported that the number of steps and the 
time required for purification was reduced when protein was fused with six or more 
additional histidine residues at the end of C- or N-terminus [66, 67].  Hu et al purified 
chimeric baculovirus with histidine tag using a simple immobilized metal affinity 
chromatography (IMAC) with a high purity of 87%.  This method is far simpler than the 
conventional methods using multiple ultracentrifugation steps.  Sonia et al used another 
form of a single step metal chelating chromatography to purify a His-tagged chimeric D-
amino acid oxidase, and the purified protein showed a highly specific enzyme activity 
with 82% yield.  To optimize the production of recombinant protein, a variety of 
expression systems has been developed and evaluated. 
The development of novel protein expression systems has been a major feature 
and challenge in biotechnology community [68, 69].  The choice of protein expression 
system needs to be determined by the use of the product, not for the ease production, 
since recombinant proteins designed for human use require specific glycosylation to 
guarantee proper cellular targeting [69].  Escherichia coli and Chinese hamster ovary 
(CHO) have been the most common expression systems to produce recombinant proteins 
[68, 70].  Over the past three decades, E. Coli has been widely used as a cellular host for 
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protein expression. However, E. coli as a prokaryotic host is not able to fold foreign 
proteins properly and cannot perform other post-transitional modifications, and typically 
does not secrete these proteins [71, 72].  Since E. coli cannot mimic mammalian 
glycosylation to produce eukaryotic proteins, the proteins have a tendency to be 
misfolded and biologically inactive [73].  Thus, E. coli has constraint in the types of 
proteins that can be expressed, such as human insulin gene, which is a relatively modest-
size and simple structure gene that can be incorporated into prokaryotic cells for gene 
expression. 
On the other hand, CHO cells as a mammalian system have been most broadly 
used expression system for the production of complex human glycoproteins [74].  CHO 
cells are enable to produce glycoproteins similar to human glycosylation patterns, but the 
glycan structures formed from CHO cells are not truly identical to those produced in 
human cells, which requires a modification to assure therapeutic use [75, 76]. There are 
major disadvantages for using mammalian cells.  The cost of maintenance and cell 
growth in mammalian cells is expensive, the process of screening takes longer time, and 
transmitting virus and prions is the issue [77].  
Another useful expression system for the production of eukaryotic proteins is the 
use of the methylotrophic yeast  Pichia pastoris, which has become popular recently [71].  
P. pastoris is a eukaryote, therefore, it provides the potential for producing soluble, 
correctly folded recombinant proteins that have undergone all the post-translational 
modifications required for functionality [71].  Another benefit of the P. pastoris is the use 
of strong alcohol oxidase promoters that are able to drive the expression of a foreign 
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gene(s) of interest, which results in large production of the target protein(s) with relative 
technical ease and at a lower cost than most other eukaryotic systems[78]. 
In the past, a numerous chimeric proteins have been expressed in a various 
expression systems mentioned above and the review of three antithrombogenic chimeric 
proteins expressed in E. coli, CHO cell, and P. pastoris are followed.  A chimeric protein, 
rscu-PA-40kDa/Hir, combining the functional properties of a fibrin –specific 
palsminogen activator with the inhibitory potential of a specific and potent thrombin 
inhibitory, was obtained by fusion of the C-terminal amino acids 53-65 hirudin (Hir) to 
the C-terminal of a 40-kDa fragment (Ser47—Leu411) of recombinant single-chain 
urokinase-type palaminogen activator (recu-PA) via a 14 –amino acid linker sequence 
[79].  The protein was produced by expression of the corresponding chimeric cDNA in E. 
coli in order to use in thrombolytic therapy of myocardial infarction and purified using 
silica gel column.  The eluted protein was further purified by chromatography on copper 
chelate and carboxymethyl-cellulose matrices.  The purified rscu-PA-40kDa/Hir reduced 
thrombin concentration to 50% at 95nM compared to 4.7nM of hirudin, and the catalytic 
efficacies for plasmin-meditated conversion to two-chain molecules were comparable for 
rscu-PA-40kDa/Hir and rscu-PA (0.63 and 0.65pM-1s-1, respectively).  Thus, the intrinsic 
specific thrombin inhibitory activity of hirudin was not fully expressed, but the activity 
was compatible with that of hirugen, indicating that a higher concentrations of the 
chimera was required for inhibit of blood coagulation in the circulation than lysis of a 
fibrin clot.  A chimeric protein, rscu-PA-40kDa/Hir, maintained the specific fibrinolytic 
and plasminogen activating activity of rscu-PA as well as its finbrinolytic potency in 
plasma.  Another novel chimeric protein, tissue plaminogen activator (t-PA), was 
15 
 
constructed by fusion of t-PA without the first three domains (finger domain, growth 
factor domain, and kringle 1) with kringle 2 serine protease domain of t-PA via 7 amino 
acid, GHRP-SYQ with high fibrin affinity [80].  Deletion of first three domains in t-PA 
prolongs its half-life while addition of GHRP-SYQ to truncated t-PA compensates for 
diminished fibrin affinity due to finger domain that is a responsible for fibrin affinity.  A 
chimeric truncated t-PA was expressed in Chinese Hamster Ovarian (CHO) cell and 
purified by the one-step purification procedure using HiTrap Benzamidine FF (high sub) 
column.  The expression level of chimeric truncated t-PA was 566,917 IU/mg and 752 
IU/ml with 86% of fibrin affinity of full length t-PA at fibrinogen concentration of 
0.2mg/ml, based on amidolytic assay.   The results demonstrated this novel chimeric t-PA 
could be a promising approach to treat thrombotic disease because the fibrin binding 
capacity of commercial form, Reteplase, was only 30% of that of full-length form [81].  
The last chimeric to review is thrombin inhibitor, dipetarudin, and it is expressed in 
expressed in P. pastoris using pPIC9 vector to compare the production of the same 
chimera in E. coli[82].  Dipetarudin has 64 amino acids and three disulfide bonds 
composed of the N-terminal head structure of dipetalogastin II and the exosite 1blocking 
segment of hirudin, connected by a five glycine linker.  Although, dipetarudin was 
initially expressed in E. coli, but the yield of purified protein was low with 0.3mg/l [83].   
The yield of dipetarudin in P.patoris was 500-fold higher than the yield obtained with the 
E. coli system, 150mg/l and 0.3mg/l respectively,  and kinetic studies showed that 
dipetarudin isolated from P. pastoris inhibited the thrombin catalytic activity with an 
apparent inhibition constant (Ki) of 399+/- 83fM[82] , which is consistent with the value 
of 446+/- 85fM for the inhibitor isolated from E. coli[83].  In this report, cloning of 
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dipetarudin in P. pastoris allowed a high-yield production, which can be increased more 
by using fermentation technology.    
Upon review of the expression systems and other chimeric proteins expressed in 
the past, this study propose to synthesize APC generating chimeric proteins, chimera I 
protein (EPCR-myc-TM2-His6) and chimera II protein (EPCR-flag-2MT-His6), as follow.  
EPCR (1-193, binding of PC and APC) was fused to TM2 (4th-6th EGF-like domain, 
binding of TR) via a linker protein, myc for chimera I and flag for chimera II, followed 
by six additional histidine to simplify the purification steps. The sequence of TM2 in 
chimera II protein is reversed. Figure 2 shows the native form of EPCR and TM and the 
functional domains used for this study. The synthetic genes encoding functional element 
of EPCR and TM is expressed in yeast, Pichia pastoris X-33 strain. This study shows the 
expression, purification and biological activity characterization of chimeric protein 
containing EPCR and TM.  
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Figure 2.   Schematic representation of TM and EPCR and functional domains used 
for chimeric proteins The 5th and 6th EGF-like domain of TM are binding site for 
thrombin and 4th EGF-like domain is enhancing the activation of Protein C. EPCR has N-
linked glycosylation site at 32, 49, and 121 and O-linked glycosylation site at 185 and 
188. 
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Materials and Methods 
Oligonucleotide design of chimeric genes 
To construct chimera I (EPCR-myc-TM-His6) and chimera II (EPCR-flag-TM-
His6), the gene sequence of EPCR-1(residue 1-193 for chimera I and chimera II) was 
obtained from GenBank accession no. L35545 and the gene sequence of mutant TM-2 
(residue Asp226 to Lys466for chimera I and residue Ala224 to Cys462 for chimera II) was 
obtained from GenBank accession no. BC035602. A myc epitope (EQKLISEEDL) and a 
flag epitope (DYKDDDDK) were used as a linker to connect EPCR and TM for chimera 
I and chimera II, respectively.  His-tag was added at the end of TM-2 to aid protein 
purification, and the amino sequence of TM-2 in chimera II was reversed. Xho I and Not 
I restriction sites were designed in the gene sequence to help direct insertion into pPICZ α 
A vector for protein expression analysis in Pichia pastoris.   
Chimera I (1395 bp) 
 
 
Chimera II (1416 bp) 
 
Figure 3.   Illustration of Chimera I and Chimera II genes. 
 
Oligo design for chimera I was done with the Gene2Oligo software of Rouillard 
and others (2004), and the oligo design for chimera II was prepared by internally 
developed oligo design software of Louw and others (2010).  The codon optimized 
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oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA). 
KOD Hot Start polymerase was obtained from Novagen (Madison, WI). Linker protein 
myc was purchased from Invitrogen and flag was purchased from Sigma.  A gel elute 
extraction kit was obtained from Qiagen (CA). 
The gene of TM2-His was constructed with residues from Ala224 to Cys462.  The 
gene of EPCR-His was constructed with residues from 1 to 193.  In addition, His-tag was 
added to the gene sequence for helping purification. Xho I and Not I restriction sites were 
designed in the gene sequence to help direct insertion into pPICZ α A vector for protein 
expression analysis in Pichia pastoris.   
TM2-His (752bP) 
 
 
EPCR-LL-His (612bP) 
 
Figure 4.   Illustration of EPCR-1 and TM2 chimeric genes. 
 
Oligo design of EPCR-His was done with the Gene2Oligo software of Rouillard 
and others (2004), and the oligo design for TM2-His was prepared by internally 
developed oligo design software of Louw and others (2010).  The codon optimized 
oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA). 
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KOD Hot Start polymerase was obtained from Novagen (Madison, WI).  A gel elute 
extraction kit was obtained from Qiagen (CA). 
PCA synthesis of chimeric genes 
The PCA (Stemmer et al., 1995) product of each chimera was carried out in a 25 
µl volume containing 0.1 µM of each oligonucleotide, 200 µM of each dNTP, 4 mM 
MgSO4, 400 µg/ml non-acetylated BSA and 0.5 units KOD Hot-Start Polymerase in 1X 
manufacturer’s buffer from Novagen (Madison, WI).  25nM of each oligonucleotide was 
used in the equimolar PCA reaction.  PCA was performed under the following 
conditions: a 30 second hot start at 92°C followed by 30 cycles of 92°C for 1 second and 
56°C for 10 seconds and 72°C for 10 seconds, and a final extension at 72°C for 
15seconds.   
Assembly PCR and amplification of chimera 
2ul of PCA product of each chimera was used as template for PCR amplification 
with 0.7uM of forward primer and reverse primer.  PCR amplification was conducted 
under the following conditions: 30 seconds hot start at 94°C, followed by 35 cycles of 
94°C of 2 seconds and 58°C for 3 seconds and 72°C for 10 seconds, and a final extension 
at 72°C for 15 seconds  
Vector constructions and expression of chimera genes in a Pichia pastoris  
After amplification, gel-purified PCR products of chimera I and chimera II were 
cloned into TOPO vector using Zero Blunt ® TOPO® PCR cloning kit from Invitrogen 
(Carlsbad, CA).  The DNA plasmids were transformed into chemically competent cells of 
E. coli strain TOP-10 from Invitrogen. 10-50ul from each transformation was spread on a 
prewarmed LB plates (1% tryptone, 0.5% yeast extract, 1% NaCl, and 1.5% agar, pH 7.0) 
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containing 50ug/ml kanamycin and incubated overnight at 37°C.  Ten positive clones of 
transformants from chimera I and chimera II were selected and transferred into 5ml of LB 
medium (1% tryptone, 0.5% yeast extract, and 1% NaCl pH 7.0) containing 50ug/ml 
kanamycin to be cultured overnight at 37°C.  Then, DNA plasmids from chimera I and 
chimera II were isolated by using PureLink™ Quick Plasmid Miniprep kit (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s manual. The overnight cell culture was 
centrifuged to separate the pellet from medium.  The pellet was lysed and loaded to the 
spin column to be eluted. Eluted DNA plasmids were sequenced at University of 
Nebraska-Medical Center sequencing facility with gene specific primers. Sequence 
analysis was performed using ChromasPro v1.5 software. 
Primers Sequence 
M13 Reverse 5'-CAGGAAACAGCTATGAC-3' 
M13 Forward 5'-GTAAAACGACGGCCAG-3' 
Table 1.   List of sequence primers used for subcloned chimera I and chimera II into 
TOPO vector 
Sequence verified clones from chimera I and chimera II were digested with Xho I 
and Not I for 3hours at 37˚C and then directionally inserted into pPICZ α A vector that 
was digested with the same enzymes. The plasmids were transformed into chemically 
competent cells of E. coli strain TOP-10 from Invitrogen (Carlsbad, CA) according to 
manufacturer’s protocol. 50-100ul of each transformants were spread on a prewarmed LB 
plates (1% tryptone, 0.5% yeast extract, 0.5% NaCl, and 1.5% agar, pH 7.0 ) containing 
25ug/ml Zeocin and incubated overnight at 37°C.  Ten positive clones from chimera I 
and chimera II were selected and transferred into 5ml of LB medium (1% tryptone, 0.5% 
yeast extract, and 0.5% NaCl pH 7.0) containing 25ug/ml Zeocin to be cultured overnight 
at 37°C.  Then, DNA plasmids from chimera I and chimera II was isolated by using 
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PureLink™ Quick Plasmid Miniprep kit from Invitrogen (Carlsbad, CA) and the isolated 
DNA plasmids from positive clones were sequenced at University of Nebraska-Medical 
Center sequencing facility with gene specific primers. Sequence analysis was performed 
using ChromasPro v1.5 software. 
  primer name sequence 
Chimera II 5' Pichia  5’-GACTGGTTCCAATTGACAAGC-3’ 
  3' Pichia 5'-GCAAATGGCATTCTGACATCC-3' 
  α Factor 5'-TACTATTGCCAGCATTGCTGC-3' 
  New F1 5´- CTCAGGTTACCTCTGGAGTTG  -3´ 
Chimera I 5' Pichia  5’-GACTGGTTCCAATTGACAAGC-3’ 
  3' Pichia 5'-GCAAATGGCATTCTGACATCC-3' 
  α Factor 5'-TACTATTGCCAGCATTGCTGC-3' 
  Old F1 5´- AAGTCACCTCTGGAGTTGTC  -3´ 
Table 2.   List of primers used for sequence analysis of chimera I and chimera II 
gene after ligation with pPICZ α A vector 
For EPCR-His and TM2-His, each PCR product was directly inserted into pPICZ 
α A vector that was digested with the same enzymes. The rest of procedure was as same 
as described above for chimera I and chimera II.  
  
primer 
name sequence 
TM2 -His 5' Pichia  5’-GACTGGTTCCAATTGACAAGC-3’ 
EPCR-His 3' Pichia 5'-GCAAATGGCATTCTGACATCC-3' 
  α Factor 5'-TACTATTGCCAGCATTGCTGC-3' 
Table 3.   List of primers used for sequence analysis of TM2-His and EPCR-His 
gene after ligation with pPICZ α A vector 
One of sequence verified clones from TM2-His were transferred into 5ml of LB 
medium (1% tryptone, 0.5% yeast extract, and 0.5% NaCl, pH 7.0) containing 25ug/ml 
Zeocin and incubated overnight at 37°C. DNA plasmids were isolated with Quigen gel 
extraction kit (Valencia, CA).  These isolated plasmids were linearized with Pme I and 
transformed into electrocompetent cells of Pichia strain X-33 according to the 
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manufacturer’s protocol from Invitrogen.  The cells were pulsed in a 0.2cm Gene Pulser® 
cuvette (Bio-Rad, Hercules, CA) at 2.0 kV, 300 Ω and 25 μF and 1ml of ice-cold 1M 
sorbitol was immediately added. 200-300ul of transformants from TM2-His were spread 
on prewarmed YSDS palate (1% of yeast extract, 2% of soy peptone, 2% dextrose, 1M 
sorbitol, and 2% agar) containing 100ug/ml Zeocin and 500ug/ml Zeocin and incubated 
at 30°C for 3-10 days until colonies formed.  
 
Figure 5.   Map of pPICZ α A vector from Invitrogen with cloning sites. pPICZ α A 
vector contains 5’ AOX1 promoter for methanol-inducible, high level expression of the 
gene interest in Pichia, α-factor secretion signal for efficient secretion of protein from 
Pichia, AOX1 transcription termination region for permitting efficient 3’ mRNA 
processing, Zeocin resistance gene for selection of transformants in E. Coli and Pichia 
and pUC origin for replication and maintenance of the plasmid in E. Coli. 
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Figure 6.   Illustration of ligated Pichia vector and chimeric genes.   
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Optimization of Induction Time 
In order to achieve a higher expression level of recombinant proteins in P. 
pastoris, the induction time of chimera I, chimera II, and TM2-His in a shake flask was 
carried out.  A single recombinant P. pastoris colony of chimera I, chimera II, and TM2-
His was selected from YSD plates (1% yeast extract, 2% soy peptone, 2% Dextrose, and 
2% agar) with 100μg/ml Zeocin and inoculated into 3ml of YSD medium (1% yeast 
extract, 2% soy peptone, and 2% Dextrose).  The cell culture was incubated at 30˚C and 
250rpm in a rotary shaker until OD600 reached to 2 -6.  The overnight cell culture was 
transferred into a 50ml baffled flask with 15ml of BMGY medium (1% yeast extract, 2% 
soy peptone, 1% glycerol, 1.34% YNB without amino acids, 4x10-5% biotin, and 100mM 
potassium phosphate, pH 6.0) with starting OD600 at 0.05 and incubated at 30˚C and 
250rpm until OD600 reached to 2 -6.  Cells were harvested and resuspended in a 50ml 
baffled flask with 15ml of BMMY medium (1% yeast extract, 2% soy peptone, 1% 
glycerol, 1.34% YNB without amino acids, 4x10-5% biotin, and 100mM potassium 
phosphate,  pH 6.0) containing 1% methanol.  The cells were allowed to grow for 96 
hours at 30˚C and 250rpm in a rotary shaker.  To maintain induction level, 100% 
methanol was added to a final concentration of methanol at 1% every 12 hours. 500μl of 
cells were collected every 12 hours after addition of 100% methanol for western blotting 
analysis. The cells were harvested at 3,000xg for 5minutes at 4˚C and the supernatant and 
pellets were stored at -80˚C for western blotting. 
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Figure 7.   Schematic optimal induction time study of chimera in a shake flask.   
Transformed Pichia strains encoding chimeric gene were first grown in 5ml YSD, 
followed by 15ml of BMGY and 15ml of BMMY.  Methanol was added to the cell 
culture every 12hours in order to keep the induction level and protease inhibitor (PMSF) 
was added after first 12hours induction.  500ul of cell culture was taken from each shake 
flask at every 12hours. Supernatants were separated from pellets via centrifugation and 
pellets were lysed. Supernatant and pellet were stored at -80C for western blotting 
analysis.  
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Large Scale Expression of Recombinant Proteins  
 After an optimal induction time for chimera I, chimera II, and TM2-His was 
determined, Pichia strain X-33 cells encoding chimera I, chimera II, and TM2-His gene 
were inoculated into a two different one liter flask. Each flask had 80ml of BMGY 
medium (1% yeast extract, 2% soy peptone, 100mM potassium phosphate, pH 6.0 with 
1.34% YNB, 4x10-5% biotin, and 1% glycerol, pH 6.0) and the starting OD600 was 0.05.  
The cells were incubated at 30˚C and 250rpm in a rotary shaker until OD600 reached to 2 -
6.  Cells from each flask were harvested and resuspended in a clean one liter flask with 
80ml of BMMY medium (1% yeast extract, 2% soy peptone, 100mM potassium 
phosphate, pH 6.0 with 1.34% YNB, 4x10-5% biotin, and 1% glycerol, pH 6.0) 
containing 1% methanol.  The cell culture was allowed to be incubated for an optimal 
induction time corresponding to each recombinant protein.  Methanol was added every 12 
hours to induce expression of the recombinant genes. Pichia strain X-33 cells encoding 
each recombinant gene were harvest by centrifugation at 3,000xg for 5min and the 
supernatant and pellets were stored at -80˚C for SDS-PAGE and Western blotting. 
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Figure 8.   Schematic Expression Strategy for Chimera I and Chimera II (A) and 
EPCR-1-His and TM2-His (B)   Chimera I and Chimera II were subcloned into TOPO 
vector using Zero Blunt ® TOPO® PCR cloning kit from Invitrogen (Carlsbad, CA) and 
transformed into E. Coli.  Selected clones were sequenced and cloned into pPICZ α A 
vector, followed by transformation into Pichia strain X-33 cells via electroporation.   
Transfomants were selected by Zeocin and sequenced.  Sequence verified clones were 
grown in YSD, BMGY, and BMMY. Supernatants were separated from the pellets via 
centrifugation and stored at -80˚C for further analysis (A). EPCR-His and TM2-His were 
directly cloned into pPICZ α A vector followed by transformation into Pichia strain X-33 
cells via electroporation.   Transfomants were selected by Zeocin and sequenced.  
Sequence verified clones were grown in YSD, BMGY, and BMMY. Supernatants were 
separated from the pellets via centrifugation and stored at -80˚C for further analysis (B). 
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Protein extraction and purification 
For secreted proteins, the supernatants were removed from growth medium by 
centrifugation at 3,000xg for 5 min. Total volume of supernatant from chimera I, chimera 
II, and TM2-His was 160 ml each. Supernatant was dialyzed against five liters of dialysis 
buffer (10mM PBS, pH 7.0) for four hours, followed by eight hours dialysis against fresh 
five liters of dialysis buffer and another four hours dialysis against fresh five liters of 
fresh dialysis buffer at 4˚C. Dialyzed supernatant was concentrated down to 20 ml via 
lyophilization. Concentrated supernatant was resuspended with 20 ml of 3X binding 
buffer, followed by 10 ml of 1X binding buffer. The resuspended mixture was purified 
with Novagen His-Bind Resin (EMD Chemicals Inc., San Diego, CA) according to the 
manufacturer’s manual.  Purified proteins were analyzed by SDS-PAGE and Western 
blotting. 
For proteins that were expressed inside the cell, pellets from each recombinant 
protein were lysed to extract proteins. Total mass of pellets for chimera I, chimera II, and 
TM2-His was 10 grams each. The pellets were resuspended with 16ml of lysis buffer 
(50mM Tris-HCl, 10mM MgSO4, 1mM EDTA, 10mM Potassium acetate, 1mM 
Dithiothreitol, and 2mM Phenylmethanesulphonyfluoride in methanol, pH 9.5). 16 ml of 
ice-cold glass beads (Biospec, Bartlesville, OK) were added and vortexed for 20 seconds, 
followed by 20 seconds of resting on the ice. The process was repeated 15 times.  54ml of 
1X binding buffer was added to the proteins extracted from pellets and the mixture was 
purified according to the Novagen His Bind Resin manual (EMD Chemicals Inc., San 
Diego, CA).   
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Figure 9.   Schematic purification strategy of chimeric proteins.  Supernatant from a 
large scale (2X 80mL) expression of chimeric protein was separated from pellet via 
centrifugation and the pellets were lysed. Total 160ml of supernatant from each chimera 
was dialyzed against 10mM PBS pH 7.5 and the total volume was 200ml, followed by 
lyophilization to bring the volume down to 20ml.  54ml of 1X binding buffer was added 
to lyophilized supernatant and purified with Novagen His-Bind resin (EMD Chemicals 
Inc., San Diego, CA) in a batch mode. Eluted proteins were diafiltered with Sartorius 
stedium biotech Vivaspin 4 from Fisher Scientific (Pittsburgh, PA) to be concentrated. A 
soluble lysate from pellets was mixed with 20ml of 3X binding buffer and 10ml of 1X 
binding buffer, and purified with Novagen His-Bind resin from EMD (Gibbstwon, NJ) in 
a batch mode. Eluted proteins were diafiltered with Sartorius stedium biotech Vivaspin 4 
(Fisher Scientific, Pittsburgh, PA) to be concentrated. 
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Western blotting 
 For Western blotting, 10 ml of supernatant of chimera I, TM2-His, and EPCR-His 
was concentrated to 2 ml via lyophilization. 4ml of chimera II was diafiltered against 
10mM PBS, pH 7.5 and concentrated to 200 μl via lyophilization. Protein samples 
obtained from supernatant were prepared under reducing condition. 10 μl of LDS buffer 
(Invitrogen, Carlsbad, CA), 4 μl of reducing agent (Invitrogen, Carlsbad, CA), and 16 μl 
of water were added to 10 μl of chimera I, TM2-His, and EPCR-His and 30 μl of chimera 
II from processed supernatant above. Protein samples obtained from pellet lysate were 
prepared under reducing condition. 2.5 μl of 4X LDS buffer (Invitrogen, Carlsbad, CA), 
1 μl of reducing agent (Invitrogen, Carlsbad, CA), and 1.5 μl of water were added to 5 μl 
of chimera I, chimera II, TM2-His, and EPCR-His.  These prepared samples were heated 
at 100˚C for 10 minutes, cooled down on the ice, centrifuged for 1 min at 13,000 rpm, 
and loaded on 4-12% Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA). The proteins 
were separated by gel electrophoresis with NuPAGE MOPS SDS Running Buffer at 200 
V for 50 minutes.  Proteins were electroblotted onto a PVDF membrane (Millipore, 
Billerica, MA) by applying 23 volts for 35 minutes and then probed with a mouse 
monoclonal antibody against histidine (1:100), a rabbit polyclonal antibody against 
EPCR (1:1000), a mouse monoclonal antibody against human thrombomodulin (1:1000), 
a mouse monoclonal antibody against myc (1:5000) and a mouse monoclonal antibody 
against flag (1:1000). The signals were visualized with Pierce ECL Western blotting 
substrate (Fisher Scientific, Pittsburgh, PA) and hyperfilm ECL (Amersham Biosciences, 
Piscataway, NJ).   
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For partially pure proteins, the protein samples were prepared under reducing 
condition.  10ul of LDS buffer (Invitrogen, Carlsbad, CA) and 4ul of reducing agent 
(Invitrogen, Carlsbad, CA) was added to partially pure protein from pellet lysate of 
chimera I (7ul), TM2-His (10ul), and chimera II (10ul). The rest of sample volume was 
filled up with water to make a total volume of 40 μl. 10ul of LDS buffer (Invitrogen, 
Carlsbad, CA) and 4ul of reducing agent (Invitrogen, Carlsbad, CA) was added to 
partially pure protein from supernatant TM2-His (1.5ul), chimera I (2ul), and EPCR-His 
(2ul). The rest of sample volume was filled up with water to make a total volume of 40 
μl. These samples were heated at 100˚C for 10 minutes, cooled down on the ice, 
centrifuged for 1min at 13,000 rpm, and loaded on 4-12% Bis-Tris NuPAGE gels 
(Invitrogen, Carlsbad, CA). The proteins were separated by gel electrophoresis with 
NuPAGE MOPS SDS Running Buffer at 200 V for 50 minutes.  Proteins were 
electroblotted onto a PVDF membrane (Millipore, Billerica, MA) by applying 23 volts 
for 35 minutes and then probed with a mouse monoclonal antibody against histidine 
(1:100).  The signals were visualized with Pierce ECL Western blotting substrate (Fisher 
Scientific, Pittsburgh, PA) and hyperfilm ECL (Amersham Biosciences, Piscataway, NJ) 
 
Binding ability of partially pure proteins with human Protein C and human α 
thrombin 
To check the binding ability of partially pure proteins with human protein C (hPC, 
Enzyme Research Labs, South Bend, IN) and human α thrombin (Enzyme Research 
Labs, South Bend, IN), the protein samples were prepared under reducing condition in 
the same manner explained above.  Electroblotted proteins on a PVDF membrane was 
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incubated with 2 μg/ml human protein C and 2 μg /ml thrombin.  The signals were 
visualized with Pierce ECL Western blotting substrate (Fisher Scientific, Pittsburgh, PA) 
and hyperfilm ECL (Amersham Biosciences, Piscataway, NJ). 
Primary antibody 
  
Host 
Animal Manufacturer Cat # Vendor Dilution
anti-His Mouse Calbiochem 13/45/31/2
EMD 
bioscience (1:100) 
anti-
EPCR  Rabbit Zymed 40-2900 Invitrogen (1:1000)
 anti-TM Mouse abcam 6980 abcam (1:1000)
 anti-myc Mouse Invitrogen R950-25 Invitrogen (1:5000)
 anti-flag Mouse Sigma F1804 Sigma (1:1000)
Table 4.   List of primary antibodies used for detection of proteins expressed in 
Pichia strain of X-33 cell. 
 
Secondary antibody 
    Manufacturer Cat # Vendor Dilution 
anti-His anti-Mouse KPL 074-1806 KPL (1:2000)
anti-EPCR  anti-rabbit KPL 074-1506 KPL (1:1000)
 anti-TM anti-Mouse KPL 074-1806 KPL (1:1000)
 anti-myc anti-Mouse KPL 074-1806 KPL (1:1000)
 anti-flag anti-Mouse KPL 074-1806 KPL (1:5000)
Table 5.   List of secondary antibodies used for detection of proteins expressed in 
Pichia strain of X-33 cell. 
 
Protein MW (kDa) Cat # Manufacturer 
Human Protein C 62 HPC1001 Enzyme Research lab 
human α thrombin 37 HT1002a Enzyme Research lab 
Table 6.   List of proteins used in binding ability of proteins expressed in Pichia 
strain of X-33 cell with human protein C and human α thrombin. 
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Antibody Cat # Manufacturer Dilution
HRP-conjugated anti-human protein C 
SHPC-
180 Enzyme Research lab (1:1000)
HRP-conjugated anti-human α 
thrombin 
SHAT-
140 Enzyme Research lab (1:1000)
Table 7.   List of HRP conjugated antibodies used in binding ability of proteins 
expressed in Pichia strain of X-33 cell with human protein C and human α 
thrombin. 
 
 
 
SDS-PAGE 
Proteins that were partially purified from supernatant and pellet lysate were 
analyzed by SDS-PAGE gel electrophoresis on a 4-12% Bis-Tris NuPAGE gels 
(Invitrogen, Carlsbad, CA) under reducing condition.  For partially purified protein from 
pellet lysate, 10 μl of LDS buffer (Invitrogen, Carlsbad, CA) and 4 μl of reducing agent 
(Invitrogen, Carlsbad, CA) were added to chimera I (7ul), TM2-His (10ul), and chimera 
II (10ul). The rest of sample volume was filled up with water to make a total volume of 
40 μl. For partially purified protein from supernatant, 10ul of LDS buffer (Invitrogen, 
Carlsbad, CA) and 4ul of reducing agent (Invitrogen, Carlsbad, CA) were added to TM2-
His (1.5ul), chimera I (2ul), and EPCR-His (2ul). The rest of sample volume was filled 
up with water to make a total volume of 40 μl. These samples were heated at 100˚C for 
10 minutes, cooled down on the ice, centrifuged for 1 minute at 13,000 rpm, and loaded 
on 4-12% Bis-Tris NuPAGE gels (Invitrogen, Carlsbad, CA). The gel was run at 200 V 
for 50 minutes. Proteins were visualized by staining with Silver Quest™ Silver Staining 
Kit (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. After gel 
electrophoresis, the gel was fixed in fixative solution for overnight, followed by 
incubation in staining solution for 15 minutes and in developing solution until the bands 
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were visualized in the gel. Once the desired band intensity was achieved 10 ml of stopper 
solution was added to the gel.  
 
Solution Phase Protein C Activation Assay 
 
The ability of partially pure chimera I and TM2-His to catalyze the activation of 
protein C was assayed in the solution phase.  Protein solutions ofTM2-His, chimera I, 
human α thrombin (TR, Enzyme Research Labs, South Bend, IN), human Protein C 
(hPC, Enzyme Research Labs, South Bend, IN), and human activated Protein C (aPC, 
Enzyme Research Labs, South Bend, IN), were prepared in reaction buffer (0.1 M NaCl, 
0.003 M CaCl2, 0.0006 M MgCl2, 0.02 M Tris-HCl, 0.1 mg/ml Bovine Serum Albumin, 
pH 7.5).  For chimera I, 25 μl of reaction buffer, 25 μl of a 0.05 mg/ml hPC solution, and 
a various concentration of partially pure chimera I from supernatant and pellet lysate 
were incubated for 15 minutes at room temperature in a sterile 96 well cell culture plate 
(Fisher Scientific, Pittsburgh, PA).  At the same time, 25μl of reaction buffer and 25μl of 
a 0.05 mg/ml hPC solution were incubated for 15 minutes at room temperature in the 
same cell culture plate, followed by addition of 25 μl of various concentration of partially 
pure TM2-His from supernatant and pellet lysate. Finally, 25 μl 0.03 μg/ml TR was 
added to the reaction mixture of chimera I and TMs-His, which was incubated at 37˚C for 
30 minutes.  For the standard curve of activated Protein C, 100 μl of various 
concentration of human activated Protein C was added to the same 96 well cell culture 
plate. To measure the amount of activated PC from each well, 25 μl of spectrozyme aPC 
(American Diagnostica Inc., Stamford, CT) was added to a final concentration of 
0.0004M.  The reaction was incubated at 37˚C and the absorbance was taken after 0, 30 
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and 60 minutes at 405 nm using a Beckman Coulter AD 340 UV/Vis microplate reader.  
The concentration of generated APC was calculated using an APC in reaction buffer 
calibration curve on the same cell culture plate. 
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Results 
Vector construction and expression of chimeric genes in a Pichia pastoris  
Upon the completion of subcloning chimera I and chimera II into TOPO vector, 
ten clones each from experiment were selected and were further sequenced to ascertain 
the DNA sequence of the desired insert comparing the reference sequence of insert. The 
clones that are determined to possess the correct sequence (sequences are listed in the 
Appendix) listed in Table 8.  
After sequence verification, clone #1 from chimera I and clone #2 from chimera II 
were selected to further insertion into pPICZ α A vector.  The PCR product of TM2-His 
was directly inserted into a pPICZ α A vector.  Table 9 shows that five clones from 
chimera I, eight clones from chimera II, and six clones from TM2-His are in frame with 
pPICZ α A vector.  Error free Clone #1-6 from chimera I, #2-4 from chimera II, and #1 
from TM2-His were selected for expression in Pichia host X-33 strain. 
Optimization of Induction Time 
Clones were first expressed in small scale cultures (~15 ml) and Western blotting 
was performed to aid in the selection of viable clones for further growth and optimization 
in a large scale expression (~80 ml). Typically, all clones were grown up to 96 hours and 
samples were taken at 24, 48 and 96 hours. Figure 10 shows the result of Western blot 
analysis on the samples obtained at 24 hour induction time from small scale culture. 
Panel-A shows the supernatants obtained from transformed Pichia cells carrying the gene 
for chimera-I. Based on observed band intensities, clones R2, R6 and R7 were chosen for 
further western blot analysis.  Panel-B shows the supernatants obtained from transformed 
Pichia cells carrying the gene for chimera-II. Based on observed band intensities, clones 
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O3 and R2 were chosen for further western blot analysis. Panel-C shows the supernatants 
obtained from transformed Pichia cells carrying the gene for TM2-His. Based on 
observed band intensities, clones O1, O4, and R2 were chosen for further western blot 
analysis. 
In the next step, samples obtained at 24, 48, and 96 hour from selected clones 
were also analyzed by western blot analysis (Figure 11/12/13).  With increasing induction 
time, all selected clones show higher levels of expression. Clone z100 R2 from chimera I, 
z100 R2 from chimera II, and z100 O1 from TM2-His show stronger signal, implying 
higher expression. Based on the band intensity, Pichia cells carrying the gene for chimera 
I was grown up to 48 hours, Pichia cells carrying the gene for chimera II was grown up 
to 96 hours , and Pichia cells carrying the gene for TM2-His was grown up to 96 hours in 
a large scale culture. 
Large Scale Expression of Recombinant Proteins  
 The samples obtained at 24, 48, and 96 hours of supernatant and pellet lysate from 
a large scale culture were analyzed by Western blotting analysis to confirm the 
expression levels of selected clones. Figure 14 shows clone #1-6 z100 R2 carrying 
genetic elements encoding chimera I in Pichia strain of X-33 cell. Figure 15 shows clone 
#2-4 z100 R2 carrying genetic elements encoding Chimera II in Pichia strain of X-33 
cell. Figure 16 shows clone #1 z100 O1 carrying genetic elements encoding TM2-His in 
Pichia strain of X-33 cell. With increasing induction time, all selected clones show 
higher levels of expression. In the next step, supernatant and pellet lysate of chimera I at 
48 hour, chimera II at 96 hour, and TM2-His at 96 hour were subjected to further 
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Western blot analysis to confirm whether each chimeric protein preserves all genetic 
elements.   
Detection of expressed chimera I, chimera II, and TM2-His protein 
 Proteins obtained from supernatant and pellet lysate of chimera I, chimera II, and 
TM2-His were detected by western blot analysis with various antibodies.  First, reduced 
Western blots probed with a mouse monoclonal antibody against histidine are shown in 
Figure 17. Panel-A shows the proteins obtained from the supernatant of TM2-His (lane 
1), EPCR-His (lane 2), chimera I (lane 3), and chimera II (lane 4).  The expected 
molecular weight of TM2-His was 42 kDa and the protein was detected at 42 kDa. The 
expected molecular weight of EPCR-His was 38 kDa and the protein was detected at 38 
kDa. The expected molecular weight of chimera I was 78 kDa and the protein was 
detected at 78 kDa with a light protein band around 40 kDa. The expected molecular 
weight of chimera II was 78 kDa and the protein was detected at 78 kDa with a light 
protein band around 40 kDa. Panel-B shows the proteins obtained from the pellet lysate 
of TM2-His (lane 1), chimera I (lane 2), and chimera II (lane 3). All proteins from the 
pellet lysate show multiple bands with a band at their expected molecular weight. 
Second, reduced Western blots probed with a rabbit polyclonal antibody against 
EPCR are shown in Figure 18. Panel-I shows the proteins obtained from the supernatant 
of EPCR-His (lane 1), chimera I (lane 2), and chimera II (lane 3).  The expected 
molecular weight of EPCR-His was 38 kDa and the protein was detected as expected. 
The expected molecular weight of chimera I was 78 kDa and the protein was detected at 
78 kDa with a light protein band around 40 kDa. The expected molecular weight of 
chimera II was 78 kDa and the protein was detected at 78 kDa with a light protein band 
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around 40 kDa. Panel-II shows the proteins obtained from the pellet lysate of TM2-His 
(lane 1), chimera I (lane 2), and chimera II (lane 3). All proteins from the pellet lysate 
show multiple bands, and chimera II has a strong signal at 78 kDa. 
Third, reduced Western blots probed with a mouse monoclonal antibody against 
thrombomodulin are shown in Figure 19. Panel-I shows the proteins obtained from the 
supernatant of TM2-His (lane 1), EPCR-His (lane 2), chimera I (lane 3), and chimera II 
(lane 4).  The expected molecular weight of TM2-His was 42 kDa and the protein was 
detected as expected. EPCR-His was not detected. The expected molecular weight of 
chimera I was 78 kDa and the protein was detected at 78 kDa with a light protein band 
around 40 kDa. The expected molecular weight of chimera II was 78 kDa and the protein 
was detected at 78 kDa with a light protein band around 40 kDa. Panel-II shows the 
proteins obtained from pellet lysate of TM2-His (lane 1), chimera I (lane 2), and chimera 
II (lane 3). All proteins from the pellet lysate show multiple bands with a band at the 
expected molecular weight. 
Fourth, reduced Western blots probed with a mouse monoclonal antibody against 
myc are shown in Figure 20. Panel-I shows the proteins obtained from the supernatant of 
TM2-His (lane 1), EPCR-His (lane 2), and chimera I (lane 3). TM2-His and EPCR-His 
was not detected. The expected molecular weight of chimera I was 78 kDa and the 
protein was detected at 78 kDa with a light protein band around 40 kDa. Panel-II shows 
the proteins obtained from the pellet lysate of TM2-His (lane 1), chimera I (lane 2), and 
chimera II (lane 3). TM2-His and chimera II were not detected on the blot. The expected 
molecular weight of chimera I was 78 kDa and the protein was detected at 78 kDa with 
other multiple bands. 
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Fifth, reduced Western blots probed with a mouse monoclonal antibody against 
flag are shown in Figure 21. Panel-I shows the proteins obtained from the supernatant of 
TM2-His (lane 1), EPCR-His (lane 2), chimera I (lane 3), and chimera II (lane 4).  The 
expected molecular weight of chimera II was 78 kDa and the protein was detected at 78 
kDa with a strong protein band around 40 kDa and other bands. TM2-His, EPCR-His, 
and chimera I were not detected on the blot. Panel-II shows the proteins obtained from 
the pellet lysate of TM2-His (lane 1), chimera I (lane 2), and chimera II (lane 3). All 
proteins from the pellet lysate show multiple bands. The results of Western blot analysis 
to detect the functional elements and the linkers of chimeric proteins are summarized in 
Table 10. 
Western blot analysis of proteins obtained from His-resin purification 
Proteins of chimera I, chimera II, TM2-His and EPCR-His obtained from His-
resin purification were analyzed to check the purity of these proteins by Western blot 
with an antibody against histidine. The expected molecular weight of chimera I, chimera 
II, TM2-His, EPCR-His was 78, 78, 42, and 38 kDa, respectively. Figure 22 shows 
proteins from the pellet lysate of TM2-His (lane 1), chimera II (lane 2), and chimera I 
(lane 3) and proteins from the supernatant of EPCR-His (lane 4), TM2-His (lane 5), 
chimera II (lane 6), chimera I (lane 7), and EPCR-His (lane 8). Most of proteins were 
detected at their corresponding molecular weight along with multiple bands. Protein from 
the supernatant of chimera II (lane 6) was not detected at all and protein from the 
supernatant of EPCR-His (lane 8) was barely detected with a faint signal.  
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Silver staining analysis of proteins obtained from His-resin purification 
 Proteins of chimer I, chimera II, TM2-His and EPCR-His obtained from His-resin 
purification were analyzed to check the purity of these proteins were analyzed by SDS-
PAGE  and silver staining (Figure 23). The expected molecular weight of chimera I, 
chimera II, TM2-His, EPCR-His was 78, 78, 42, 38 kDa, respectively. Proteins from the 
pellet lysate of chimera I (lane 1), chimera II (lane 2), and TM2-His (lane 3) have 
multiple bands. All of purified proteins have a band at 62 kDa. Proteins from the 
supernatant of TM2-His (lane 5), chimera I (lane 7), and EPCR-His (lane 9), and have 
multiple bands.  TM2-His (lane 5) has one band at 42 kDa with other multiple bands. 
Chimera I (lane 7) has one band at 45 kDa and the other band at 62 kDa. EPCR-His (lane 
4), chimera I (lane 6), and EPCR-His (lane 8) have only one band at 62 kDa.  
Binding ability of partially pure proteins with human Protein C and human α 
thrombin 
 Figure 24 shows that partially pure proteins of chimera I, chimera II, TM2-His, 
and EPCR-His, were electroblotted, incubated with human protein C, and detected with a 
HRP-conjugated anti-human protein C. All of proteins are bound to human protein C, 
except for protein from the supernatant of chimera II (lane 6). Figure 25 shows that 
partially pure proteins of chimera I, chimera II, TM2-His, and EPCR-His, were 
electroblotted, incubated with human α thrombin, and detected with a HRP-conjugated 
anti-human α thrombin. All of proteins are bound to human α thrombin, except for 
protein from the supernatant of chimera II (lane 6) and EPCR-His (lane 8). 
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Solution Phase Protein C Activation Assay 
The ability of partially pure chimera I and TM2-His to catalyze the activation of 
Protein C was assayed in the solution phase.  We used the APC values obtained from 
4762, 2381, 595, and 297 nM of TM2-His (supernatant) in the experiment to extrapolate 
the APC value of 961 nM of TM2-His (supernatant). To extrapolate the APC values of 
320 nM and 160 nM of TM2-His (pellet), we used the APC values obtained from 595 and 
297 nM of TM2-His (pellet) in the experiment. The final APC values presented in this 
study were averaged from 30 minute and 60 minute reading at 405 nm after the activation 
of Protein C.  
Figure 26 shows the amount of APC generated from partially pure proteins of 
chimera I and TM2-His. Chimera I (supernatant) at 961 nM produced 0.979 nM of APC, 
chimera I (pellet) at 320 nM produced 3.768 nM of APC, and chimera I (pellet) at 160 
nM produced 1.370 nM of APC. TM2-His (supernatant) at 961 nM produced 0.540 nM 
of APC, TM2-His (pellet) at 320 nM produced 2.048 nM of APC, and TM2-His (pellet) 
at 160 nM produced 0.676 nM of APC. Human Protein C alone, thrombin alone, or 
human Protein C and thrombomodulin together did not produced activated Protein C. The 
control sample produced 9.1 nM of APC with commercial proteins of hPC, rabbit Lung 
TM, and thrombin in the absence of EPCR. 
Overall the activity level of chimera I is twice higher than that of TM2-His at the 
same concentration of proteins from both supernatant and pellet lysate, and the activity 
level of protein from the pellet lysate is higher than that of proteins from the supernatant. 
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(A) Chimera I, Supernatant,24hr (B) Chimera II, Supernatant,24hr (C) TM2-His, Supernatant,24 hr 
Figure 10.  Western blotting analysis of small scale induction experiments probed 
with anti-His. Selected clones of Pichia cells carrying the gene for chimera I, chimera II, 
and TM2-His were first grown in BMGY, followed by BMMY and fractions were 
analyzed at 24 hours induction in cell culture. Supernatants were separated from via 
centrifugation and pellets were lysed. Supernatants were analyzed by western blotting 
and probed with a mouse monoclonal antibody against. (Z100: Zeocin 100 µg/ml, z 500: 
Zeocin 500 µg/ml, O: original plate, R: restreaked plate) 
 
 
 
     (A) Chimera I, Supernatant                       (B) Chimera I, Pellet lysate 
Figure 11.  Western blotting analysis of small scale induction experiment probed 
with anti-His.  Pichia cells carrying the gene for chimera I (clone #1-6) were first grown 
in BMGY, followed by BMMY and fractions were analyzed at 24, 48, and 96 hours upon 
induction in cell culture. Supernatants were separated from via centrifugation and pellets 
were lysed. 10 µl of supernatant and 5 µl of soluble lysate from pellet were analyzed by 
Western blotting and probed with a mouse monoclonal antibody against histidine.  (Z100: 
Zeocin 100 µg/ml, R: restreaked plate) 
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          (A) Chimera II, Supernatant                       (B) Chimera II, Pellet lysate 
Figure 12.  Western blotting analysis of small scale induction experiment probed 
with anti-His. Pichia cells carrying the gene for chimera II (clone #2-4) were first grown 
in BMGY, followed by BMMY and fractions were analyzed at 24, 48, and 96 hours upon 
induction in cell culture. Supernatants were separated from via centrifugation and pellets 
were lysed. 30 µl of supernatant and 5 µl of soluble lysate from pellet were analyzed by 
Western blotting and probed with a mouse monoclonal antibody against histidine.  (Z100: 
Zeocin 100 µg/ml, O: original plate, R: restreaked plate). 
   
 
 
 
          (A) TM2-His, Supernatant                                  (B) TM2-His, Pellet lysate 
Figure 13.   Western blotting analysis of small scale induction experiment probed 
with anti-His. Pichia cells carrying the gene for TM2-His (clone #1) were first grown in 
BMGY, followed by BMMY and fractions were analyzed at 24, 48, and 96 hours upon 
induction in cell culture. Supernatants were separated from via centrifugation and pellets 
were lysed. 10 µl of supernatant and 5µl of soluble lysate from pellet were analyzed by 
Western blotting and probed with a mouse monoclonal antibody against histidine.  (Z100: 
Zeocin 100 µg/ml, O: original plate, R: restreaked plate).  
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(A) Chimera I, Supernatant                   (B) Chimera I, Pellet lysate 
Figure 14.  Western blotting analysis of large scale induction experiment probed 
with anti-His. Pichia cells carrying the gene for chimera I (clone #1-6z100 R2) were 
first grown in BMGY, followed by BMMY and fractions were analyzed at 24 and 48 
hours upon induction in cell culture. Supernatants were separated from via centrifugation 
and pellets were lysed. 10 µl of supernatant and 5 µl of soluble lysate from pellet were 
analyzed by Western blotting and probed with a mouse monoclonal antibody against 
histidine.   
 
 
        (A) Chimera II, Supernatant                          (B) Chimera II, Pellet lysate 
Figure 15.  Western blotting analysis of large scale induction experiment probed 
with anti-His. Pichia cells carrying the gene for chimera II (clone #2-4 z100 R2) were 
first grown in BMGY, followed by BMMY and fractions were analyzed at 24 and 48 
hours upon induction in cell culture. Supernatants were separated from via centrifugation 
and pellets were lysed. 30 µl of supernatant and 5 µl of soluble lysate from pellet were 
analyzed by Western blotting and probed with a mouse monoclonal antibody against 
histidine.   
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         (A) TM2-His, Supernatant                                   (B) TM2-His, Pellet lysate 
Figure 16. Western blotting analysis of large scale induction experiment probed 
with anti-His. Pichia cells carrying the gene for TM2-His (clone #1 z100 O1) were first 
grown in BMGY, followed by BMMY and fractions were analyzed at 24, 48, and 96 
hours upon induction in cell culture. Supernatants were separated from via centrifugation 
and pellets were lysed. 10 µl of supernatant and 5ul of soluble lysate from pellet were 
analyzed by Western blotting and probed with a mouse monoclonal antibody against 
histidine.  
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        (A) Supernatant before purification         (B) Pellet lysate before purification  
 
Figure 17.  Western blotting analysis of proteins expressed in Pichia Pastoris probed 
with anti-His. Transformed Pichia strains were first grown in BMGY, followed by 
BMMY. Supernatants were separated from via centrifugation and pellets were lysed.  
Supernatant and soluble lysate from pellet were analyzed by western blotting and probed 
with a mouse monoclonal antibody against histidine. (I) P: positive control (Positope), 
lane 1: TM2-His (5X concentrated), lane 2: EPCR-His (5X concentrated), lane 3: 
Chimera I (5X concentrated), lane 4: Chimera II (20X concentrated) (II) P: positive 
control (Positope), lane 1: TM2-His, lane 2: Chimera I, lane 3: Chimera II 
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   (A) Supernatant before purification               (B) Pellet lysate before purification 
Figure 18. Western blotting analysis of chimeric proteins expressed in Pichia 
Pastoris probed with anti-EPCR. Transformed Pichia strains were first grown in 
BMGY, followed by BMMY. Supernatants were separated from via centrifugation and 
pellets were lysed.  Supernatant and soluble lysate from pellet were analyzed by western 
blotting and probed with a rabbit polyclonal antibody against EPCR. (I) P: positive 
control (143.5ng of EPCR-LL), lane 1: EPCR-His (5X concentrated), lane 2: Chimera I 
(5X concentrated), lane 3: Chimera II (20X concentrated) (II) P: positive control 
(143.5ng of EPCR-LL), lane 1: TM2-His, lane 2: Chimera I, lane 3: Chimera II 
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(A) Supernatant before purification                (B) Pellet lysate before purification 
 
Figure 19. Western blotting analysis of chimeric proteins expressed in Pichia 
Pastoris probed with anti-TM. Transformed Pichia strains were first grown in BMGY, 
followed by BMMY. Supernatants were separated from via centrifugation and pellets 
were lysed.  Supernatant and soluble lysate from pellet were analyzed by western blotting 
and probed with a mouse monoclonal antibody against thrombomodulin. (I) P: positive 
control (50ng of human Thrombomodulin), lane 1: TM2-His (5X concentrated), lane 2: 
EPCR-His (5X concentrated), lane 3: Chimera I (5X concentrated), lane 4: Chimera 
II_20X concentrated (II) P: positive control (100ng of human Thrombomodulin), lane 1: 
TM2-His, lane 2: Chimera I, lane 3: Chimera II 
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     (A) Supernatant before purification           (B) Pellet lysate before purification 
 
Figure 20. Western blotting analysis of chimeric proteins expressed in Pichia 
Pastoris probed with anti-myc. Transformed Pichia strains were first grown in BMGY, 
followed by BMMY. Supernatants were separated from via centrifugation and pellets 
were lysed.  Supernatant and soluble lysate from pellet were analyzed by western blotting 
and probed with a mouse monoclonal antibody against myc. (I) P: positive control (250ng 
of Positope), lane 1: TM2-His (5X concentrated), lane 2: Chimera I (5X concentrated), 
lane 3: Chimera II (20X concentrated) (II) P: positive control (250ng of Positope), lane 1: 
TM2-His, lane 2: Chimera I, lane 3: Chimera II 
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  (A) Supernatant before purification                (B) Pellet lysate before purification
 
Figure 21. Western blotting analysis of chimeric proteins expressed in Pichia 
Pastoris probed with anti-flag. Transformed Pichia strains were first grown in BMGY, 
followed by BMMY. Supernatants were separated from via centrifugation and pellets 
were lysed.  Supernatant and soluble lysate from pellet were analyzed by western blotting 
and probed with a mouse monoclonal antibody against flag. (I) P: positive control (50ng 
of flag fusion protein), lane 1: TM2-His (5X concentrated), lane 2: EPCR-His (5X 
concentrated), lane 3: Chimera I (5X concentrated), lane 4: Chimera II (20X 
concentrated) (II) P: positive control (50ng of flag fusion protein), lane 1: TM2-His, lane 
2: Chimera I, lane 3: Chimera I 
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Figure 22   Western blotting analysis of His-resin purified chimeric proteins 
expressed in Pichia Pastoris probed with anti-His. Transformed Pichia strains were 
first grown in BMGY, followed by BMMY. Supernatants were separated from via 
centrifugation and pellets were lysed.  Supernatant and soluble lysate from pellet were 
purified by His-resin and analyzed by western blotting and probed with a mouse 
monoclonal antibody against histidine. (I) P: positive control (Positope), lane 1: TM2-His 
from pellet, lane 2: Chimera II from pellet, lane 3: Chimera I from pellet, lane 4: EPCR-
His from supernatant, lane 5: TM2-His from supernatant, lane 6: Chimera II from 
supernatant, lane7: Chimera I from supernatant, lane 4: EPCR-His from supernatant. 
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Figure 23.   SDS-PAGE analysis of His-resin purified chimeric proteins expressed in 
Pichia Pastoris with silver staining. Transformed Pichia strains were first grown in 
BMGY, followed by BMMY. Supernatants were separated from via centrifugation and 
pellets were lysed.  Supernatant and soluble lysate from pellet were purified by His-resin 
and analyzed by SDS-PAGE with silver staining. Lane1: TM2-His from pellet, lane 2: 
Chimera II from pellet, lane 3: Chimera I from pellet, lane 4: EPCR-His from desalted 
supernatant, lane 5: TM2-His from supernatant, lane 6: Chimera II from supernatant, lane 
7: Chimera I from supernatant, lane 8: EPCR-His from desalted/lyophilized supernatant, 
lane 9: EPCR-His from desalted supernatant. 
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Figure 24.   Western blotting analysis of His-resin purified chimeric proteins 
expressed in Pichia pastoris to check the binding ability with human protein C. 
Transformed Pichia strains were first grown in BMGY, followed by BMMY. 
Supernatants were separated from via centrifugation and pellets were lysed.  Supernatant 
and soluble lysate from pellet were purified by His-resin and analyzed by western 
blotting and incubated with 2ug/ml human protein C overnight at 4C. The signal was 
detected with a HRP-conjugated sheep anti-human protein C. (I) P: positive control 
(500ng human protein C), lane 1: TM2-His from pellet, lane 2: Chimera II from pellet, 
lane 3: Chimera I from pellet, lane 4: EPCR-His from supernatant, lane 5: TM2-His from 
supernatant, lane 6: Chimera I from supernatant, lane7: Chimera II from supernatant, lane 
4: EPCR-His from supernatant. 
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Figure 25. Western blotting analysis of His-resin purified chimeric proteins 
expressed in Pichia pastoris to check the binding ability with human α thrombin. 
Transformed Pichia strains were first grown in BMGY, followed by BMMY. 
Supernatants were separated from via centrifugation and pellets were lysed.  Supernatant 
and soluble lysate from pellet were purified by His-resin and analyzed by western 
blotting and incubated with 2ug/ml human α thrombin overnight at 4C. The signal was 
detected with a HRP-conjugated sheep anti- human α thrombin. (I) P: positive control 
(500ng human protein C), lane 1: TM2-His from pellet, lane 2: Chimera II from pellet, 
lane 3: Chimera I from pellet, lane 4: EPCR-His from supernatant, lane 5: TM2-His from 
supernatant, lane 6: Chimera I from supernatant, lane7: Chimera II from supernatant, lane 
4: EPCR-His from supernatant. 
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Figure 26.   Solution phase Protein C activation assay of purified chimera I and 
TM2-His from supernatant. Protein solutions ofTM2-His, chimera I, human α 
thrombin, human Protein C, human activated Protein C, were prepared in reaction buffer.  
For chimera I, 25 μl of reaction buffer, 25 μl of a 0.05 mg/ml hPC solution, and a various 
concentration of partially pure chimera I from supernatant and pellet lysate were 
incubated for 15 minutes at room temperature in a sterile 96 well cell culture plate.  At 
the same time, 25μl of reaction buffer and 25μl of a 0.05 mg/ml hPC solution were 
incubated for 15 minutes at room temperature in the same cell culture plate, followed by 
addition of 25 μl of various concentration of partially pure TM2-His from supernatant 
and pellet lysate. Finally, 25 μl 0.03 μg/ml TR was added to the reaction mixture of 
chimera I and TMs-His, which was incubated at 37˚C for 30 minutes.  For the standard 
curve of activated Protein C, 100 µl of various concentration of human activated Protein 
C was added to the same 96 well cell culture plate. To measure the amount of activated 
PC from each well, 25 μl of Spectrozyme aPC was added to a final concentration of 
0.0004M.  The reaction was incubated at 37˚C and the absorbance was taken after 0, 30 
and 60 minute at 405 nm using a Beckman Coulter AD 340 UV/Vis microplate reader.  
The concentration of generated APC was calculated using an APC in reaction buffer 
calibration curve on the same cell culture plate. 
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Name of chimera Composition & Size Positive clones 
chimera I EPCR-myc-TM2-His6 (1395 bp) #1, #4, #8 
chimera II EPCR-flag-2MT-His6 (1416 bp) #2 
Table 8.   Sequence result of subcloned chimera I and chimera II with TOPO vector. 
After amplification, gel-purified PCR products of chimera I and chimera II were 
subcloned into TOPO vector.  The DNA plasmids were transformed into chemically 
competent cells of E. coli strain TOP-10. 10-50 µl from each transformation was spread 
on a pre-warmed LB plates containing 50 µg/ml kanamycin and incubated overnight at 
37°C.  Ten positive clones of transformants from each chimera were selected and 
transferred into 5ml of LB medium containing 50 µg/ml kanamycin to be cultured 
overnight at 37°C.  Then, plasmid DNA from each chimera was isolated and was 
sequenced at University of Nebraska-Medical Center sequencing facility with gene 
specific primers. Sequence analysis was performed using ChromasPro v1.5 software. 
 
 
 
 
 
Name  Composition  Positive clones 
chimera I EPCR-myc-TM2-His6  #1-2, #1-4, #1-6, #1-7, #1-9 
chimera II EPCR-flag-2MT-His6 #2-1, #2-2, #2-3, #2-4, #2-6, #2-7, #2-8, #2-9
TM2-His 2MT-His6 #1, #2, #6, #10, #11, #13 
Table 9.   Cloning results of chimera I, chimera II, and TM2-His with pPICZ α A 
vector. Clones from chimera I, chimera II, and TM2-His were digested by Xho I and Not 
I for 3hours at 37˚C and then directionally ligated with pPICZ α A vector that was 
digested with the same enzymes. The ligated plasmid was transformed into chemically 
competent cells of E. coli strain TOP-10 according to manufacturer’s protocol. 50-100 µl 
of each transformants were spread on a prewarmed LB plates containing 25 µg/ml Zeocin 
and incubated overnight at 37°C.  Ten positive clones from each transformant were 
selected and transferred into 5ml of LB medium containing 25 µg/ml Zeocin to be 
cultured overnight at 37°C.  Then, plasmid DNA from each chimera was isolated and 
sequenced at University of Nebraska-Medical Center sequencing facility with gene 
specific primers. Sequence analysis was performed using ChromasPro v1.5 software. 
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   Pellet lysate  Supernatant 
  
TM2‐His  Chimera 
I 
Chimera 
II 
TM2‐
His (5X)
Chimera I 
(5X) 
Chimera 
II (20X) 
EPCR‐LL‐
His (5X) 
anti‐His  +  +  +  +  +  +  + 
anti‐EPCR  ‐  +  +  ‐  +  +  + 
anti‐TM  +  +  +  +  +  +  ‐ 
anti‐myc  ‐  +  ‐  ‐  +  ‐  ‐ 
anti‐flag  ‐  ‐  +  ‐  ‐  +  ‐ 
Table 10.   Summary of Western blotting analysis with various antibodies to detect 
the functional elements and the linkers of chimeric proteins 
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Discussion 
 The goal of this study is to express genes encoding the functional elements of 
EPCR and TM in an attempt to generate APC in-situ. The synthetic genes encoding 
chimera I, chimera II, and TM2-His were successfully expressed in yeast Pichia host X-
33 strain. However, the expression and purification of these chimeric proteins need 
improvement to enhance secretion of mature protein and obtain pure chimeric proteins of 
chimera I, chimera II and TM2-His. When Pichia cells carrying the gene for chimera I 
was grown up to 96 hours, the overexpression was observed on Western blotting analysis. 
To resolve this issue, chimera I was grown up to 48 hours (Figure 11). Overall, the 
expression level of all chimeric proteins from the pellet lysate was as high as that of 
chimeric proteins from the supernatant, which indicated that the secretion of mature 
protein into the medium was not sufficient. Secretion of mature protein is important since 
it allows easy and efficient purification from the extracellular medium [84]. The purpose 
of using pPICZ α A vector in this study is to secrete mature protein into the medium with 
α-factor leader sequence. The partial secretion of chimeric proteins in this study might be 
due to the ineffective signal cleavage at Kex2 cleavage site. To provide a hydrophilic 
environment at Kex2 cleavage site, the addition of (Glu-Ala)2 is recommended, which 
will be further removed by Ste 13 dipeptidyl aminopeptidase [85, 86]. Brake et al. 
suggested that the repeating residue of (Glu-Ala) was not necessary for a proper 
processing of fusion protein hEGF, but the presence of repeating sequence of (Glu-Ala) 
might prevent the accumulation of intracellular active α-factor and be essential for the 
correct folding of fusion between α-factor leader and foreign proteins. 
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 Along with the partial secretion of chimeric proteins, proteolytic degradation of 
secreted chimeric proteins has been observed in Figure 17/18/19/20/21.  All crude 
chimeric proteins from the supernatant have multiple small fragments with a strong band 
at their expected molecular weight. These small fragments are caused by the inactivation 
of protease inhibitors in an aqueous reaction environment over a 48 hour period [87] even 
though 2 mM of PMSF (Phenylmethanesulphonyfluoride, protease inhibitor) in 100% 
methanol has been added to the cell culture at the first 12 hour induction.  A large amount 
of oxygen consumption for methanol induction and additional methanol feeding every 12 
hours contribute to the accumulation of hydrogen peroxide as a by-product inside the cell, 
which can cause oxidative stress on the cell to bring out more protease activity. Sinha et 
al. reported that proteolytic activity was observed when the carbon source switched from 
glycerol to methanol and reached a maximum between 60 to 72 hours induction time 
[88]. In this sense, the lower molecular weight fragments of chimera I protein and 
chimera II proteins are suspected to be a truncated form of chimeric proteins caused by 
the proteolytic activity. Both chimera I protein and chimera II protein show a strong band 
at the expected molecular weight of 78 kDa with another strong band at 40 kDa. Li et al. 
have observed the similar phenomena in the attempt of producing 58 and 75 kDa fusion 
proteins, MBP-FXa-cargo-mcy-His6 [89]. All these proteins had a band at 45 kDa 
corresponding molecular weight of MBP, and Li et al. suggested that the proteolysis 
occurred at or close to FXa or in the C-terminal MBP region. For chimera I protein and 
chimera II protein, the proteolysis occurred in the C-terminal EPCR region since both 
these proteins were detected with anti-His, anti-EPCR, ant-His, and anti-myc/anti-flag. 
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To reduce the photolytic degradation of secreted proteins, it is important to explore the 
choice of protease inhibitor with reduced induction times on methanol.  
 Another interesting fact is that the expression level of Pichia cells carrying the 
genes for  chimera I, and chimera II, and TM2-His was different from each other (Figure 
14/15/16). The expression of Pichia cells carrying the gene for TM2-His was more 
successful than others while the expression of Pichia cells carrying the gene for chimera 
II was poor. This might be due to the composition of each chimeric protein. A chimeric 
protein TM2-His contains a partial gene sequence (EGF 4/5/6) of the whole 
thrombomodulin molecule, so the expression is much easier than the expression of 
bifunctional proteins such as chimera I and chimera II. Protein chimera I and protein 
chimera II contain both EPCR (binding of Protein C and activated Protein C) and TM 
(binding of thrombin). The expression of Pichia cells carrying the gene for chimera II is 
even worse than that of chimera I. This might be explained by the reversed amino acid 
sequence of thrombomodulin in chimera II since other elements of both genes are 
identical except for the linker protein and the order of amino acid sequence for TM. The 
reversed amino acid sequence of TM is not natural and it might affect the stability of the 
protein construction. Another important domain in chimeric protein is an appropriate 
linker peptide for the multi-functional protein to work independently by keeping the 
spatial separation of the multi-functional domains [65]. Aral et al. introduced α-helical 
linker, (EAAAK)n to separate two green fluorescent protein (GFP) variants and 
demonstrated a good separation of the functional domains and kept them independent, 
without disturbing domains.  The linker peptide used for chimera I and chimera II is a 
myc epitope and a flag epitope, respectively. These linker peptides are flexible but they 
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do not provide much space between EPCR and TM, so it might affect the biological 
function of the chimeric proteins. All these factors can contribute to the expression of 
chimeric proteins. 
 Prior to testing the biological activity of the chimeric proteins to activate Protein 
C, His-resin affinity purification is used for a single step purification of protein 
containing His-tag sequence by metal chelation chromatography. His-tag sequence binds 
to Ni2+ ion immobilized on His-bind resin in a batch mode and the results are shown in 
Figure 21 and Figure 22. The final products of the chimeric proteins are partially pure 
since every sample with silver staining has a mysterious band at 62 kDa. Especially, the 
result of EPCR-His protein purification is not agreeable with the literature reported 
previously [90]. Mamedov et al. purified the same EPCR-His protein with His-resin 
affinity column purification and the final product showed only one protein band at 38 
kDa. These results suggest that the efficiency of column purification is better than batch 
mode purification since the batch mode has a limitation in complete removal of residues 
from each step, especially after binding and washing steps.  This is probably why the 
final protein products after purification have a protein band at 62 kDa. In addition, 
purified protein from the supernatant of chimera II was not detected on both Western blot 
and silver staining. This could be the result of inappropriately handling protein samples 
along with a low expression level. After the purification, the protein sample prepared for 
Western blot analysis showed a sign of pH problem by turn into yellow instead of 
purplish blue. The sample was too acidic to run on the gel with the running buffer at 7.0, 
which led to an aggregation of protein sample in the gel well. This could be fixed by a 
series of dialysis immediately after purification to remove a residual imidazole from 
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elution buffer. Proteins purified from the pellet lysates show numerous protein bands on 
silver staining, which is occurred by a combination of a strong proteolytic activity inside 
the cell and degradation of protein due to inadequate protease inhibitor use. The cell lysis 
buffer used in this study contains protease inhibitors, 1 mM of EDTA and 2 mM of 
PMSF, but the combination of EDTA and PMSF is not sufficient to prevent the 
degradation of protein. More options for protease inhibitors need to be explored and 
shorten induction times to reduce the amount of vacuolar proteases and hydrogen 
peroxide accumulation inside the cell. In spite of all the issues, the biological activity of 
the final protein products was tested. 
Solution phase assay was conducted to demonstrate that chimera I protein and 
TM2-His protein were biologically active to catalyze activation of Protein C (Figure 26). 
Chimera I protein and TM2-His protein activated the Protein C; however, the activity of 
these two proteins  is much less than that of control with commercial proteins of hPC, 
rabbit lung TM, and thrombin in the absence of EPCR. The activity of control is ~80-fold 
higher than chimera I protein from pellet lysate and ~910-fold higher than chimera I 
protein from supernatant. The activity of control is ~180-fold higher than TM2-His 
protein from pellet lysate and ~1600-fold higher than TM2-His protein from supernatant. 
In addition, the activity of proteins from pellet lysate generated more APC than proteins 
from supernatant. It is possible that the protein from pellet lysate still remain the α-factor 
signal sequence so it might alter the protein folding process inside the cell, which might 
affect the function of protein. Nonetheless, the overall activity of chimera I protein is 
almost 2-fold higher than that of TM2-His protein. The activity ratio of chimera I and 
TM2-His is 1.8 at 961 nM (supernatant), 1.84 at 320 nM (pellet), and 2.0 at 160 nM 
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(pellet). This can be explained by the unique molecular composition of chimera I (EPCR-
flag-2MT-His6). While thrombomodulin in TM2-His protein activates Protein C only by 
forming a complex with a thrombin, EPCR in chimera I protein stimulates Protein C 
activation mediated by the thrombin/thrombomodulin complex [37].  The Gla-domain of 
PC/APC interacts with EPCR [33], and the Gla-domain of PC also interacts with TM 
and/or TR[49].  The result of PC activation assay proves our hypothesis that 
incorporating EPCR with TM in the chimeric protein can stimulate the activation of 
Protein C better than TM alone. 
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Conclusion 
The synthetic genes encoding chimera I, chimera II, and TM2-His have been 
successfully expressed in the yeast, Pichia pastoris X-33 strain. Overall, expression level 
of chimera I, chimera II, and TM2-His is low, and mature proteins are partially secreted 
into the medium, and the final products of purified proteins were partially pure. In spite 
of all these issues, this study demonstrates that chimera I protein and TM2-His protein 
remain the biological activity to activate Protein C from the solution phase experiment. 
Further, this study has shown that the activity of chimera I is almost twice higher than 
that of TM2-His by co-expressing EPCR and TM in the chimera I protein.  
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Future Work 
This study demonstrates the expression of genes encoding functional elements of 
EPCR and TM in an attempt to generate APC in-situ and the biological activity of 
chimera I protein to activate Protein C. However, several issues need to be resolved to 
improve the production of chimeric proteins.  To optimize the secretion of target protein, 
the addition of repeated sequence of (Glu-Ala) after Kex2 cleavage site needs to be 
considered in the design of DNA sequence. To improve the function of multi-functional 
protein, the use of a helical linker between EPCR and TM might be a better choice by 
keeping the spatial separation of the multi-functional domains. To reduce or prevent the 
degradation of protein, the use of protease inhibitor cocktail is recommended for the 
induction and process of protein at any stage, which will affect the quality of final protein 
product. Once chimera I and chimera II are successfully expressed and purified, these 
proteins can be coated onto the surface of the biomaterial surfaces to delay the blood clot. 
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Appendices 
1. Chimera I Design 
a t c t c g a g a a a a g a F C S Q D A S D G L Q R L H M L Q I S Y F R D P Y H 
V W Y Q G N A S L G G H L T H V L E G P D T N T T I I Q L Q P L Q E P E S W 
A R T Q S G L Q S Y L L Q F H G L V R L V H Q E R T L A F P L T I R C F L G 
C E L P P E G S R A H V F F E V A V N G S S F V S F R P E R A L W Q A D T Q 
V T S G V V T F T L Q Q L N A Y N R T R Y E L R E F L E D T C V Q Y V Q K 
H I S A E N T K G S Q T S R S Y T S E Q K L I S E E D L N S A V D C S V E N G 
G C E H A C N A I P G A P R C Q C P A G A A L Q A D G R S C T A S A T Q S C 
N D L C E H F C V P N P D Q P G S Y S C Met C E T G Y R L A A D Q H R C E 
D V D D C I L E P S P C P Q R C V N T Q G G F E C H C Y P N Y D L V D G E C 
V E P V D P C F R A N C E Y Q C Q P L N Q T S Y L C V C A E G F A P I P H E 
P H R C Q Met F C N Q T A C P A D C D P N T Q A S C E C P E G Y I L D D G F 
I C T D I D E C E N G G F C S G V C H N L P G T F E C I C G P D S A L V R H I 
G T D C D S G K H H H H H H Stop g c g g c c g c t a  
 
Lower-case:  nucleotides  Upper Case:  Amino Acids  
Black- added sequence  Red- EPCR mature peptide  
Green- Flag epitope   Blue- TM-2 (Asp226 to Lys466) normal 
Orange- His 6 tag   Underline-Xho1 and Not1 sites 
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2.  Chimera I Starting original nucleotide sequence 
 
ATCTCGAGAAAAGATTTTGTAGTCAAGATGCTTCTGATGGTCTACAAAGATTG
CATATGTTGCAAATCTCTTACTTTCGTGATCCTTATCATGTTTGGTACCAAGGT
AATGCTTCTTTGGGTGGACATTTGACTCATGTTTTGGAAGGTCCAGATACTAA
TACTACTATCATTCAATTGCAACCTTTGCAAGAACCTGAAAGTTGGGCTCGTA
CTCAAAGTGGTTTGCAATCTTACTTGTTACAATTTCATGGTCTAGTTCGTTTGG
TTCATCAAGAACGTACTTTGGCTTTTCCTTTGACTATCCGTTGTTTTTTGGGTT
GTGAATTGCCTCCTGAAGGTTCTAGAGCTCATGTTTTTTTTGAAGTTGCTGTTA
ATGGTAGTTCTTTTGTTAGTTTTCGTCCAGAAAGAGCTTTGTGGCAAGCTGAT
ACTCAAGTCACCTCTGGAGTTGTCACCTTTACCTTGCAACAATTGAATGCTTA
CAATCGTACTCGTTATGAATTACGTGAATTTCTTGAAGATACTTGTGTTCAAT
ATGTTCAAAAACATATTTCTGCTGAAAATACTAAAGGTAGTCAAACTAGTCG
TTCTTACACTTCTGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCC
GTCGACTGTTCTGTTGAAAATGGTGGTTGTGAACATGCTTGTAATGCTATTCC
AGGTGCTCCAAGATGTCAATGTCCAGCTGGTGCTGCTTTGCAAGCTGATGGTA
GATCTTGTACTGCTTCTGCTACTCAATCTTGTAATGATTTGTGTGAACATTTCT
GTGTTCCAAATCCAGATCAACCAGGTTCTTATTCTTGTATGTGTGAAACTGGT
TATAGATTGGCTGCTGATCAACATAGATGTGAAGATGTTGATGATTGTATTTT
GGAACCATCTCCATGTCCACAAAGATGTGTTAATACTCAAGGTGGTTTCGAAT
GTCATTGTTATCCAAATTATGATTTGGTTGATGGTGAATGTGTTGAACCAGTT
GATCCATGTTTCAGAGCTAATTGTGAATATCAATGTCAACCATTGAATCAAAC
TTCTTATTTGTGTGTTTGTGCTGAAGGTTTCGCTCCAATTCCACATGAACCACA
TAGATGTCAAATGTTCTGTAATCAAACTGCTTGTCCAGCTGATTGTGATCCAA
ATACTCAAGCTTCTTGTGAATGTCCAGAAGGTTATATTTTGGATGATGGTTTC
ATTTGTACTGATATTGATGAATGTGAAAATGGTGGTTTCTGTTCTGGTGTTTG
TCATAATTTGCCAGGTACTTTCGAATGTATTTGTGGTCCAGATTCTGCTTTGGT
TAGACATATTGGTACTGATTGTGATTCTGGTAAGCATCATCACCATCACCACT
AAGCGGCCGCTA 
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3. Chimera II Design 
 
a t c t c g a g a a a a g a F C S Q D A S D G L Q R L H M L Q I S Y F R D P Y
H V W Y Q G N A S L G G H L T H V L E G P D T N T T I I Q L Q P L Q E P
E S W A R T Q S G L Q S Y L L Q F H G L V R L V H Q E R T L A F P L T I
R C F L G C E L P P E G S R A H V F F E V A V N G S S F V S F R P E R A L
W Q A D T Q V T S G V V T F T L Q Q L N A Y N R T R Y E L R E F L E D
T C V Q Y V Q K H I S A E N T K G S Q T S R S Y T S K K R K K D Y K D
D D D K K R K R K C D T G I H R V L A S D P G C I C E F T G P L N H C V
G S C F G G N E C E D I D T C I F G D D L I Y G E P C E C S A Q T N P D C
D A P C A T Q N C F M Q C R H P E H P I P A F G E A C V C L Y S T Q N L
P Q C Q Y E C N A R F C P D V P E V C E G D V L D Y N P Y C H C E F G
G Q T N V C R Q P C P S P E L I C D D V D E C R H Q D A A L R Y G T E C
M C S Y S G P Q D P N P V C F H E C L D N C S Q T A S A T C S R G D A Q
L A A G A P C Q C R P A G P I A N C A H E C G G N E V S C D W A R K K
K R H H H H H H Stop g c g g c c g c t a  
 
 
Lower-case:  nucleotides  Upper Case:  Amino Acids   
Black- added sequence  Red- EPCR mature peptide   
Green- Flag epitope   Blue- TM-2 (Ala224 to Cys462) flipped 
Orange- His 6 tag   Underline-Xho1 and Not1 sites 
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4. Chimera II Starting original nucleotide sequence 
 
ATCTCGAGAAAAGATTCTGCTCTCAAGATGCTTCTGATGGATTGCAAAGATTG
CATATGTTGCAAATTTCTTACTTCAGAGATCCTTACCACGTTTGGTACCAGGG
TAACGCTTCTTTGGGTGGACATTTGACTCACGTTTTGGAGGGTCCTGATACTA
ACACTACTATCATTCAATTGCAACCTTTGCAGGAACCTGAATCTTGGGCCAGA
ACCCAATCTGGATTGCAGTCTTACTTGTTGCAGTTTCATGGTTTGGTTAGATT
GGTTCACCAGGAGAGAACTTTGGCCTTTCCTTTGACCATTAGATGTTTCTTGG
GATGTGAATTGCCTCCAGAAGGTTCTAGAGCTCATGTTTTTTTCGAAGTTGCT
GTTAACGGTTCTTCTTTCGTTTCTTTCAGACCTGAGAGAGCCTTGTGGCAGGC
TGATACTCAGGTTACCTCTGGAGTTGTTACTTTCACCTTGCAACAGTTGAACG
CTTATAACAGAACCAGATATGAATTGAGAGAATTCTTGGAAGATACTTGTGT
TCAGTATGTTCAAAAGCACATTTCTGCCGAAAACACCAAGGGTTCTCAAACTT
CTAGATCTTACACCTCTAAGAAAAGAAAGAAGGATTACAAAGACGACGACG
ATAAGAAGAGAAAGAGAAAATGTGACACTGGTATCCACAGAGTTTTGGCTTC
TGACCCTGGATGCATTTGTGAGTTTACTGGACCTTTGAACCACTGTGTTGGTT
CTTGTTTTGGTGGTAACGAGTGTGAGGACATTGACACTTGCATTTTTGGAGAC
GATTTGATTTATGGTGAGCCATGCGAATGTTCTGCCCAAACTAACCCTGATTG
CGACGCCCCATGTGCCACTCAAAACTGTTTCATGCAGTGTAGACACCCTGAA
CATCCTATTCCAGCTTTCGGTGAAGCTTGCGTTTGTTTGTATTCTACTCAGAAC
TTGCCACAGTGCCAGTACGAGTGTAACGCTAGATTTTGCCCTGACGTTCCTGA
AGTTTGTGAGGGTGATGTTTTGGACTACAACCCATACTGTCATTGCGAATTCG
GTGGACAGACTAACGTTTGCAGACAACCTTGCCCTTCTCCAGAATTGATCTGT
GATGACGTTGATGAATGCAGACACCAGGATGCCGCCTTGAGATATGGAACCG
AATGTATGTGTTCTTATTCTGGTCCTCAAGATCCTAACCCAGTTTGTTTCCATG
AGTGCTTGGACAATTGTTCTCAGACCGCTTCTGCCACCTGTTCTAGAGGAGAT
GCCCAGTTGGCTGCTGGTGCTCCTTGCCAATGTAGACCTGCTGGTCCAATTGC
TAACTGTGCTCACGAATGTGGAGGTAATGAGGTTTCTTGTGACTGGGCTAGA
AAGAAGAAGAGACATCATCACCATCACCACTAAGCGGCCGCTA 
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5. TM2-His Design 
ATCTCGAGAAAAGA A W D C S V E N G G C E H A C N A I P G A P R C Q C P A 
G A A L Q A D G R S C T A S A T Q S C N D L C E H F C V P N P D Q P G S Y S C 
M C E T G Y R L A A D Q H R C E D V D D C I L E P S P C P Q R C V N T Q G G F 
E C H C Y P N Y D L V D G E C V E P V D P C F R A N C E Y Q C Q P L N Q T S Y 
L C V C A E G F A P I P H E P H R C Q M F C N Q T A C P A D C D P N T Q A S C 
E C P E G Y I L D D G F I C T D I D E C E N G G F C S G V C H N L P G T F E C I C 
G P D S A L V R H I G T D C  CATCATCACCATCACCACTAAGCGGCCGCTA 
Blue-TM-2 (Ala224 to Cys462) 
Underline-Xho I and Not I sites 
Orange-His 6 tag DNA sequence 
 
6. Chimera II Starting original nucleotide sequence 
ATCTC-GAG, AAA, AGA  
GCTTGGGATTGCTCTGTCGAAAATGGAGGTTGTGAACATGCTTGTAATGCCAT
CCCAGGTGCCCCAAGATGCCAGTGTCCAGCAGGAGCTGCCTTGCAAGCTGAT
GGTAGATCTTGTACCGCATCTGCAACTCAGTCCTGTAATGATTTGTGCGAGCA
CTTCTGTGTTCCTAACCCAGATCAACCTGGATCCTACTCTTGTATGTGTGAGA
CAGGTTACAGATTGGCTGCTGATCAACATAGATGTGAAGATGTTGACGACTG
TATTTTGGAACCTTCTCCATGTCCACAAAGATGTGTCAACACTCAAGGTGGTT
TTGAGTGTCATTGCTATCCAAATTACGATTTGGTTGATGGAGAGTGCGTCGAA
CCAGTTGACCCATGTTTCAGAGCTAATTGTGAGTACCAGTGCCAGCCATTGAA
TCAAACTTCCTATTTGTGTGTCTGCGCCGAAGGTTTTGCCCCAATCCCTCATG
AACCTCACAGATGTCAGATGTTTTGTAATCAGACTGCCTGTCCAGCCGACTGC
GACCCAAATACTCAGGCCTCCTGTGAATGTCCAGAAGGATACATTTTGGATG
ATGGTTTTATTTGTACAGACATTGATGAGTGTGAAAACGGTGGATTTTGTTCC
GGTGTCTGTCACAACTTGCCTGGTACTTTCGAATGCATTTGCGGACCTGATTC
CGCTTTGGTCAGACACATCGGAACTGACTGT 
CAT, CAT, CAC, CAT, CAC, CAC, TAA, GCG-GCCGCTA 
 
 
 
